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Documents that prove psilocybin mushrooms are not controlled under the UN conventions 
on psychotropic drugs and that there is no need to outlaw psilocybin mushrooms: psilocybin 
mushrooms are of low risk to the public health. 
 
The following documents are included in this pdf file: 
 
Page 2:  A letter from the senior inspector of controlled substances(Dutch ministry of health) in 
which he explains & communicates the opinion of the International Narcotics Control 
Board (UN) on Psilocybe mushrooms and preparations thereof. * 
Page 4  The risk assessment by the CAM (part of the EU early warning system) * 
Page 35  A article on the legal status or Psilocybe mushrooms by Ananda Schouten 
Page 37  Two letters from Herbert Schaepe from the INCB. 
Page 39  Acute psychological and physiological effects of psilocybin in healthy humans:  
a double-blind, placebo controlled dose-effect study.  
A new study(2004) done by Heffter Research Center & Psychiatric University Hospital 
Zurich which shows psilocybin is not hazardous to somatic health. 
 
*Translated by Ananda Schouten, Sjamaan distribution. 
 
What is the INCB?  
The International Narcotics Control Board is part of the United Nations and is there to see to it that 
countries follow the treaties on drugs and to explain & advise countries or national authorities how 
to they should interpret the UN treaties. Since the INCB is there for governments, it only 
communicates trough them and not directly to the public. This is why it’s letters are often 
communicated by other authorities. 
For a full description, see their website: www.incb.org
 
What do the UN treaties mean? 
The existence of drug laws in countries that are part of the UN, is caused directly by the UN treaties. 
Especially the UN convention on psychotropic substances of 1971. Most drug laws, like the Misuse 
of Drugs Act 1971, are almost an exact copy the UN treaties. And this is not without reason. 
Governments are bound to the treaties. 
Here you can find the UN convention: http://www.incb.org/e/conv/1971/cover.htm
http://www.unodc.org/unodc/un_treaties_and_resolutions.html
 
What is the CAM? 
The Coordination point and Monitoring New Drugs is part of the European Union’s early warning 
system. It makes risk assessments of new drugs in order to advise what would be the best way to 
deal with them. Their risk assessments have lead to the ban on GHB, 4-MTA and various other 
drugs. The CAM consists out of experts out of every related ministry; from Justice to health. 
Their risk assessment on magic mushrooms is the only one that has been made worldwide. The 
original Dutch document and English abstract can be found here: 
http://www.igz.nl/productie/bestanden/Risicoschattingsrapport%20paddos%20werkexemplaar.pdf
 
 
In order to keep this document up to date, please send related info or info that can add to the 
completeness of this compilation of documents to: Mr. Ananda Schouten Sjamaan@xs4all.nl 
De Sjamaan distribution, The Netherlands. 
This compilation of documents may be freely distributed in complete and unmodified form. 
 
 
 
 
 
This document is dated 20 September 2004. 
  
 
STATE SUPERVISION ON PUBLIC HEALTH  
 
Inspection on Health care 
               
 
P a r n a s s u s p l e i n   5         Bakker, Schut & Van der Plas 
2511  VX  The  Hague       Att.: Solicitor Mw. Mr. A.G. van der Plas 
Telephone:  +31(0)70-3407911      Prinsengracht 708 
Fax:  +31(0)70-3407159       1017 LA Amsterdam 
 
Correspondence only trough: 
Post-box 16119 
2500 BC, The Hague 
The Netherlands 
 
 
Our reference:       Information  with:   Direct  number:   The  Hague 
FMT/OW/U/2004    W.  Best    +31(0)70-3405717  15  April  2004 
Subject: 
Psilocybin mushrooms and preparations 
 
 
Dear Ms A.G. van der Plas, 
 
After your request to the INCB and the telephone conversation we had, I am hereby sending 
you an explanation concerning several definitions of terms in the law on controlled substances, 
as last changed in 2003. 
 
In the explanation of definitions in the law of controlled substances(opium law) it is written 
that a means is a substance as well as a preparation. 
A preparation is a solid or fluid mixture of substances. 
In Articles 2 and 3 is subsequently referred to the thereby belonging list I and II of controlled 
substances, where the substances and preparations controlled by this law are listed. 
On none of  both lists mushrooms are mentioned as a substance. 
In line with the reasoning of the INCB about the Convention on Psychotropic drugs of 1971 
(See below) it is impossible to make a preparation out of mushrooms like intended in the law 
on controlled substances. 
An analogue reasoning goes for the legs of a chair. None of them are controlled by one or both 
of the lists of controlled substances and are therefore not to be defined as a substance. 
Whatever one does to these legs of a chair, they can never fall under the definition of a 
preparation, defined in article 1 of the law of controlled substances.  
 
In articles 2 and 3, forbidden activities are mentioned regarding the listed substances on list I 
and II, which includes to prepare, to treat and to process. It may be clear that if a substance 
does not occur on one of both lists, then these prohibition provisions do not apply to this 
substance on basis of the law on controlled substances. 
In short, since a mushroom cannot be marked as a controlled substance and it is therefore not 
possible to make a controlled preparation from it, there is not one reason present to forbid 
preparation on basis of the law on controlled substances. 
Reverse reasoning, it is so that when one takes psilocin and/or psilocybin (substances named 
on list 1 of the law on controlled substances) and would add these to edible mushrooms, for 
example champignons, an illegal preparation would arise, as meant in the law on controlled 
substances.  
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For completeness sake I hereby, again state the point of view of the INCB, which I fully agree 
on: 
 
“As you are aware, mushrooms containing the above substances are collected and abused for 
their hallucinogenic effects. As a matter of international law, no plants (natural material) 
containing psilocin and psilocybin are at present controlled under the convention on 
psychotropic substances of 1971. Consequently, preparations of these plants are not under 
international control and therefore, not subjects to any of the articles of the 1971 convention.” 
 
This statement has been formulated by the secretariat of the INCB in consultation with the 
science department and the legal advise department of the United Nations International Drug 
Control Program. 
 
Trusting to have been of service to you, I hereby sign, 
 
With high regards, 
 
The Senior-Inspector on the law on controlled substances, 
 
 
 
 
 
 
W. Best, apothecary 
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1      Management summary 
 
The Coordination point Assessment and Monitoring new drugs (CAM) has made risk assessment 
for psychotropic mushrooms, which contain the substances psilocin and psilocybin. 
 
Because there is no physical or mental dependence, the acute intoxication is limited to panic and 
anxiety attacks and in case of chronological intoxication, at the worst flashbacks can occur. 
Therefore there is no risk for the individual health when magic mushrooms are used.  
The product is relative easily to get and there is little adequate information available for users. The 
quality of the product is unreliable and the awareness of quality by those who sell it is normally 
absent. On the other hand the proportions of the usage, the vulnerability of the user, the number 
and the seriousness of reports of incidents are low. The risk for the public health is therefore 
estimated as very low. 
This drug influences the ability to react (i.e. in traffic) in a negative way, but the drug gives no cause 
of violent behaviour by the user. Because the use takes place at home or outside city limits, there is 
no question of annoyance or disturbance for citizens. The risk of the disturbance of public order / 
peace is therefore assessed as very low. 
There is no risk of criminal involvement. At most some individuals from the smart shop circuit got 
connections with the “designer drugs scene”. 
 
Compared to other drugs, (the CAM has made risk assessment rapports for (MBDB, MTA and 
GHB)), Psilocybe mushrooms score very low on the scale of risk assessment. 
 
Looking at the above, the CAM recommends quality restrictions on the product Psilocybe 
mushrooms (i.e. standardization, cleanliness, labelling) and the trade in Psilocybe mushrooms (i.e. 
responsible information supply) and by doing this, creating a limited market for mushrooms. The 
result of the risk assessment gives no reason for a prohibition of Psilocybe mushrooms. 
 
 
 
 
 
 
   7
 
2         Risk assessment 
 
Subjoined are the arguments and the remarks described per criteria (numbered), that where 
discussed by the members of the risk assessment committee. The average score given by the 
members is written down below. 
 
2.1   Risks concerning the health of the individual 
 
1) Level of risk of physical dependence  
 
Physical dependence does not occur with mushrooms. 
 
1. none (1.1)  2. very low  3. possible  4. high  5. very high 
 
 
2) Level of psychological dependence  
 
It depends on which definition of dependence of the mind is used. If this is the same as an 
addiction, then there is no risk. However, there are users, who like the experience in such a way, 
that they would like to do it again, in such a case you could say there is a very low psychological 
dependence. 
 
1. none (1.8)  2. very low  3. possible  4. high  5. very high  
 
3) Level of the risk of acute toxicity 
 
Every now and then there are incidents where medical assistance is required (first aid, hospital 
admission). This is usually caused by anxiety- and panic attacks. The somatic effects (blood-
pressure, heartbeat etc.) are very low. The setting is very important: inexperienced tourists who are 
in an unfamiliar country use all kinds of (soft) drugs in a short period of time. When anxiety- and 
panic attacks occur, the use of mushrooms cannot always be held as the only cause.  
 
1. none  2. very low(2.3)  3. possible  4. high  5. very high 
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4) Level of the risk of chronic toxicity 
 
Psilocybe mushrooms mostly used experimental, long term use is very rare. There are examples in 
other cultures where people have used mushrooms during their live on a regular base, without any 
symptoms of chronic toxicity. There are however users which after single use experience flashbacks 
during several weeks lasting till a few months afterwards. About mutagenitec and teratogenitic is not 
enough information available to draw any conclusions, but it does not lie in the line of logic, that 
Psilocybe mushrooms would have this aspect. Just like some other soft drugs, the use of Psilocybe 
mushrooms by mentally unbalanced people can be a trigger to psychological problems. 
 
1. none   2. very low  3. possible  4. high  5. very high  
 
2.2    Risks for the public health 
 
5) Level of the risk concerning the proportion and frequency of use and the possible increase of 
use. 
 
Psilocybe mushrooms are less used then XTC; which is used remarkably less then cannabis. The 
use throughout the country in very low (ever-used 1,6%), with younger people and with certain 
populations (people who go out, tourists, truants) the use is highest. Most of the use is caused by 
experimental behaviour, this ends after a few times. Many users mention that they don’t really like 
the experience; one become unsociable, it is not to be compared with the empathic influence of 
XTC and it is therefore not suitable for use at parties. 
  
1. None   2. very Low (2.4)  3. Possible  4. High  5. Very high  
 
6) Level of risk concerning the vulnerability of the user 
 
This concerns young people (who are also using other supplements) who are still growing up. The 
Smartshop branch is telling that they advise people under the age of 18 not to use Psilocybe 
mushrooms. Mentally unbalanced persons are also slightly more at risk. (see 4.) 
 
  1. none   2. very low (2.8)  3. possible  4. high  5. very high  
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7) Level of risk caused by the absence of adequate usage information 
 
The chance that mushrooms are used wrong is present, but even when mushrooms are used in a 
wrong way; it seems that this poses few problems. Some owners of Smartshops or salesperson are 
very good informed, others not at all. Sometimes the turnover seems to be more important then 
supplying the customer of adequate information. In tourist shops this is more often true than in 
Smartshops.  
 
1. none   2. very low   3. possible  4. high  5. very high  
 
 
8) Level of risk concerning the availability of the product 
 
Mushrooms are not only sold in smart shops; also in grow shops, head shops and on the Internet 
are mushrooms available. The number sales points vary per region. In Amsterdam and the border 
areas are relative a lot of sales points. It is quite easy to get mushrooms. The stock of mushrooms 
per Smartshop is a large. There are estimations that 50% of the turnover of a Smartshop are 
coming from mushrooms. 
 
1. none   2. very low   3. possible  4. high  5. very high  
 
 
9) Level of risk by unreliable quality of the product 
 
There seems to be no big variation in composition, concentration and dosage. The biological 
variation of the active ingredient substance is about 1% till 3,5%. The differences don’t seem to 
cause major problems. In most cases there is no standardization of this natural product. It can be 
infected with fungi and mites. There is a certain risk of mistaken identification with poisonous 
species. Looking at the facts that it is easy to get Psilocybe mushrooms and the small number of 
medical incidents, there doesn’t seem to be a great deal wrong with the quality. 
 
1. none   2. very low (2.9)  3. possible  4. high  5. very high  
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10) Level of risk caused by an unreliable distribution, sales points and traders 
 
Of few smart shop owners is known that they have connections with the ‘designer drugs scene’. A 
few smart shop owners do not want to tell who supply their magic mushrooms. In this branch the 
quality awareness isn’t very high, there are exceptions. This is usually the case with tourist shops 
where mushrooms are also sold. 
 
1. none   2. very low   3. possible  4. high  5. very high  
 
11) Level of risk measured by cause and number of reports of incidents 
 
The number of reports a year did increase (from 5 to 20), but the seriousness of the incidents did 
not. Medical assistance was mainly necessary because anxiety and panic attacks occurred. 
 
1. none   2. very low  (2.5)  3. possible  4. high  5. very high  
 
2.3     Risks for public safety and order 
 
12) Level of risk concerning the frequency and seriousness of possible annoyance for citizens 
caused by sale and use 
 
The sale points of mushrooms don’t cause any annoyance and the use of Psilocybe mushrooms 
usually takes place at home or in nature. During the experience the users are focused on ‘their own 
world’. Only when a panic attack occurs one might possibly address or bother citizens.  
 
1. none (1.4)  2. very low    3. possible  4. high  5. very high  
 
13) Level of risk caused by the tendency to violence 
 
When anxiety and panic attacks occur users can react aggressive when they are appealed (by the 
competent authority). The number of panic and anxiety reactions is rather small. (see 11.) 
 
1. none (1.7)  2. low    3. possible  4. high  5. very high  
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14) Level of risk caused by the influence of the product on the ability to react 
 
There hasn’t been much investigation on this matter, but it is to be expected that this product 
influence the ability to react. Hallucinogens can cause changes in the way of acting and seeing, 
which can lead to dangerous situations for psycho motoric abilities, especially during driving or 
working with equipment. One can also become sleepy. 
 
1. none   2. low    3. possible  4. high (4.6)  5. very high  
 
2.4     Risks of criminal involvement 
 
15) Level of risk caused by involvement of (organised) crime for production and trade 
 
From some smart shop owners is known that they have connections with the synthetic drugs scene 
and in some Smartshops, which were visited by the police, controlled substances were found. There 
has been no (extensive) investigation into this. 
 
1. none (1.9)  2. low    3. possible  4. high  5. very high  
 
16) Level of risk concerning involvement of (organised) crime with production and trade in raw 
materials 
 
Refer to 15. In this case it is hard to tell the difference between the raw material and the actual 
product. 
 
1. none (1.7)  2. low    3. possible  4. high  5. very high  
 
  
2.5   Enumeration of qualitative and quantitative scores 
 
In the table below the results of the scores per category of risk are displayed. 
The numbers below show the average of the scores per criteria. In words is shown how the numeric 
scores are assessed textually. It is emphasized that the numeric scores are an aid for the risk 
assessment. For the determination of the final textual assessment are the (qualitative) arguments, 
which are used for the risk assessment, most important.  
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The directive has been used  that a score from 1 to 2 means no risk, from 2 to 3, very low risk, from 
3 to 4, a possible risk, from 4 to 5, a high risk and above the 5, a very high risk. 
 
Category risk  Score  Valuation  
I.   Health of the individual 1.8  No  risk 
II.  Public health/society  2.9  Very low risk 
III. Disturbance of peace and order  2.5  Very low risk 
IV. Criminal involvement  1.8  No risk 
Total 9.0   
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3     Conclusions and recommendations 
 
 
3.1   Conclusions concerning the procedure 
 
The risk assessment for magic mushrooms containing psilocin and psilocybin is the third following 
the established procedure and criteria of the CAM. There was reasonable much information 
available about mushrooms. The risk assessment meeting was brief (one meeting of 2.5 hours) and 
the greater part went smooth because the procedure and the criteria were known. During this 
meeting a tape recorder was used to ensure that all arguments where recorded. 
 
3.2   Conclusions concerning mushrooms 
 
Because there is no physical or psychological dependence, the acute toxic effects stays limited to 
possible panic and anxiety attacks and about chronic toxic effects at most the occurrence of 
flashbacks can be mentioned, there is no risk for the health of individuals when magic mushrooms 
are used. 
The product is relative easy to acquire and there is little adequate information available on use of 
the product. The quality of the product is unreliable and there is quality awareness is absent with 
among most of those who sell it. On the other hand, the proportion of the use, the vulnerability of 
the user and the amount and the seriousness of incidents reports are low. The risk for the public 
health is therefore estimated as very low. 
This product influences the response capacity (i.e. with driving) of the user in a negative way and 
but there is no occurrence of lowering of the violence threshold of the user. Because the use mostly 
takes place at home and in free nature there is no annoyance for citizens. The risk of disturbance of 
public peace is therefore estimated as very low. 
There is no risk concerning criminal involvement. At most few individuals in the Smartshop circuit 
have got connections with the ‘designer drugs’ scene. 
 
3.3    Position fixing on risk scale 
 
The outcome of this and of former risk assessment(s) of other products are described in the 
following table. With the evaluation of the first risk assessments that where made, the work group 
has decided to remove the category ‘remaining risks’ (image of the Netherlands, consequences of 
measurements, applicable law on comparable products) because the risk assessment comity’s duty   14
mainly concerns technical risk assessment and by judging over these aspects the comity would be 
moving to much on the territory of policy. 
To be able to make the end scores comparable anyway, the last row describes what other the other 
products would have scored if the criteria ‘remaining risks’ would not have been counted. In this 
case a product can score a minimum of 5 and a maximum of 20 on the scale of risk level. 
 
Product Individual 
health 
Public 
health 
Public order Criminality Remaining 
risks 
Total 
score 
Score 
(compared)
MBDB possible  possible  low  possible  possible  14.7  11.2 
4-MTA possible  possible  possible  possible  high  16.2  11.8 
GHB high  possible  low  low low  13.2  11.0 
Mushrooms  none  low  low  none    9.0 
    
The recommendation after the risk assessment for MBDB was to monitor for some time and then 
make a new risk assessment. This recommendation was followed by the policy. The risk 
assessment of MTA led to the recommendation of taking measures against production and trade. 
The Minister has chosen to ban it by putting it on list 1(Note of translator: Dutch list of controlled 
substances) of the Opium law, mainly because of the policy assessment to be uniform with other 
European countries. The recommendation for GHB was to monitor the situation and to make a new 
risk assessment as soon as there is a clear change in situation. The Minister has followed this 
recommendation. 
 
Compared to MBDB, MTA and GHB, magic mushrooms score lower on the risk on the individual 
health and the risk on public health, lower than MTA and equal to MBDB and GHB on the 
disturbance of peace / public order and lower than the three other products on the risk of criminality. 
Compared to the other three products magic mushrooms score remarkable low on the scale of risk 
level. 
 
3.4    Consequences of measures 
 
The risk assessment comity has briefly discussed the consequences of possible measures. It is 
aware of the situation that the judicial status of mushrooms is still to be judged by the court of law.  
The risk assessment commission points out that magic mushrooms cause few problems nationally, 
as well in the area of public health, disturbance of peace / public order and criminality. The product 
is rarely known in other Countries of the European Union (except for certain areas of Germany 
where sometimes mushrooms from The Netherlands are found).  
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Therefore it would be good to handle a low profile regarding mushrooms and to prevent 
criminalization.  
In the discussion was also brought up that in case of banning mushrooms, the Smartshops would 
lose half of their profit. This might result in them searching for other possible more risky products to 
even it up. Also the consumer could, when psilocybin mushrooms are no longer available through 
the Smartshops, decide to pick mushrooms in free nature (high risk of misidentification with toxic 
species) or consumers may switch to other products – possibly with higher risk-. 
Most of the risks that the comity signalizes concern the inconsistent composition and quality of the 
products. Also the low quality of information and that it’s easy to acquire play a part. 
 
3.5    Recommendation 
 
Looking at the things written above, the recommendation is to create quality standards to the 
product magic mushrooms (e.g. standardization, purity, labelling) and to the trade in mushrooms 
(i.e. information supply) and among others thereby promoting the limitation of the availability of 
mushrooms. The outcome of the risk assessment gives no need a ban by law on magic 
mushrooms. 
 
Further procedure 
 
The CAM offers the risk assessment report with the conclusions and the recommendation to the 
Minister of VWS (Note of the translator: Ministry of Public health). The board of policy will advice the 
Minister about the measures, which should be made in regard to the report of the CAM. A summary 
of measurements, which can be considered, are described in appendix 3. 
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Appendix 1 
 
Information rapport Psilocybe mushrooms 
 
Common information 
 
Mushrooms of the species Psilocybe ssp. and a number of other species (Conocybe, Panaeolus, 
Inocybe etc) contain psilocybin and psilocin (both are psycho-active alkaloids) as most important 
active substances. Several psilocybin mushrooms occur in Europe. The human body metabolises 
psilocybin into psilocin. These substances affect the serotonin receptors and cause an increase of 
serotonin in the brains and a temporary decrease of the concentration of noradrenalin, dopamine 
and histamine. 
Usual dose: 1 gram of dried = 10 gram of fresh mushrooms; this can cause illusions and 
hallucinations. LSD, mescaline and psilocybin probably work by means of the same 
pharmacological principles.  
 
1. Health of the individual 
 
1 / 2. Amount of risk concerning the physical and mental dependence 
 
Physical dependence does not occur with the use of psilocybin. 
Mental dependence is very rare, yet possible. 
With the effect of Psilocybe mushrooms tolerance occurs fast, meaning that a higher dosage is 
required to get the same effect. This tolerance decreases when psilocybin is not used for a 
considerable period of time. User data Information on users gives reason to estimate to assume that 
the tolerance discourages frequent use and therefore they talk about a period of at least 3 weeks 
before mushrooms can be used again to get the desired effects. 
It has not been excluded that pleasant experiences will lead the user to try to experience these 
effects again. However, the fast occurring tolerance stands in the way of frequent usage.  
 
3.    Acute toxicity 
 
The psychoactive dosage of psilocybin is about 6 to 12 mg. The lethal dosage for humans is 
estimated to be about the same, as ones own body weight in fresh mushrooms.  
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Psilocybin is therefore barely toxic (there is a case described with a good ending after eating up to 
300 mushrooms). For most herbal products goes that acute intoxications are rare. The number of 
described cases concerning intoxication by herbal products is relative small. This makes it 
impossible to draw casuistic based conclusions. When mushrooms and herbal products rise in 
popularity, there will occur more cases of intoxication, reported despite the relative low level of 
toxicity. Danger of misidentification with species of higher toxicity is prominently present. Mainly the 
switching of the Psilocybe for the Cortinarius spp. (which causes kidney insurrection) is notorious 
(known from several cases). 
As yet there are no messages of serious incidents in the Netherlands after the use of mushrooms. 
Mushrooms can be polluted with LSD, PCP or other substances. 
The most conspicuous physical appearances are large eye pupils, balance impairment, paresthesia 
(“crawling ants” all over the body, relaxing mussels, fast heartbeat, a dry mouth and nausea. Other 
effects can be: sleepiness, abdomen pain, vomiting, pseudo-hallucinations, involuntary movements, 
excitement, fever, cold feeling, accommodation impairment, watery eyes, slowed down heartbeat- 
and breathing frequency and decreased blood pressure.  
Mental phenomena: hallucinogenic connections can rake up long forgotten memories and leave a 
big impression on users. Adrenergic blockers (like neurolepticals, propanol) usually work as 
incomplete antagonists.  
After an acute intoxication the users often complain about uninterested feelings, extreme fatigue 
and depressive thoughts. Recovery is complete. 
 
4.    Chronic toxicity 
 
There has been research done, but until the present moment no proof has been found for chronic 
toxicity. 
Not enough data is available about mutagenicity and teratogenicity to draw any conclusion. There is 
no irreversible organ damage by psilocybin reported.  
 
Long-term effects can, based upon the cross tolerance with LSD, not be excluded. A user can for 
example, sometimes months later after a one-time use, experience flashbacks (re-experiencing 
parts of a trip experienced in the past). There are also very rare occasions of remaining psychiatric 
symptoms (panic attacks) described.  
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The chance of the occurrence of long-term effects is greater however,  for persons with an 
underlying psychiatric disorder.  
 
Public health/society 
 
5.    Size and frequency of use/increase of use (inter)nationally 
 
Mind-expanding mushrooms have been used for centuries in different countries in ritual and spiritual 
'settings'. Since a few decades a trend has developed in the Western society to use these 
mushrooms recreational. 
Since 1997 is the use of mushrooms becoming more popular in the Netherlands. They are 
increasingly  used for recreational purpose by young people. The rise of smart-shops and the 
presence of smart-booths in discotheques and clubs might have a big influence on the degree and 
frequency of use of mushroom products. It is plausible that large-scale use of mushrooms will lead 
to an increasing number of medical incidents. The increasing use of woodchips on paths in for 
example parks could lead to a wider spread of natural occurring mushrooms (amongst others; 
Psilocybe cyanescens).  
 
For most young people and young adults the use stays incidental, experimental and recreational. 
Many users quit after one or a couple of times. Research shows that compared to other drugs 
magic mushrooms have become popular in a relative short period of time. From students from the 
age of 12 and older, 4.3 % has used mushrooms at least one time. In absolute figures this means 
that there are between 39.000 and 43.000 students in the Netherlands, which have used a magic 
mushroom sometime. A short research study showed that 10 % of the young aged and young 
adults (age 15-24) have had experience with mushrooms. Half of those users have only used 
mushrooms once or twice in their live.  
 
The impression exists that the accessibility increases. According the most recent estimation there 
are currently about a 100 sales points in our country. 
 
6.    Level of vulnerability of the user/age/experience/knowledge/circumstances 
 
Intoxications are generally the result of switching / misidentification with a poisonous mushroom. 
Despite their experience even experts can make a fatal error. The intensity of the effect depends 
upon the dosage.  
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Especially teenagers at the age of 15-19 are experimenting (boys > girls).  
People who are very unstable, have depressive thoughts or psychiatric impairments, would have an 
increased chance on psychological complications and medical incidents. There are no ‘psychoses 
as a result of consuming psilocybin-containing mushrooms’ described. Although the toxicity of 
psilocybin containing mushrooms is very low, there is a chance on behavioural change. Suicidal 
behaviour might occur during a ‘bad trip’. There are no cases known of suicidal behaviour after the 
consumption of psilocybin containing mushrooms. It is assumed that the toxicity of psilocybin in 
children is more serious for then in adults.  
With simultaneous use of psilocybin containing mushrooms and other drugs, like alcohol or 
marihuana, synergism (mixing of sense perception) can occur.  
 
By far the majority of persons, who have experience with mushrooms, also had an experience with 
cannabis or XTC. 
 
Dosages of about 6 to 12 mg psilocybin can lead to illusions and hallucinations. These can occur 
several times a minute and are usually visual by nature: the user sees for example colourful moving 
patterns. These images can be experienced as a pleasant, but also as frightening. Additionally, 
described are feelings of decrease of inhibition, periods of intense laughter and euphoria, but also 
restlessness, anxiety, panic and depressive thoughts. Between the hallucinations the user is well 
accessible for conversation. It is possible to verbally reach the user during the hallucinations. It is 
unpredictable weather the user will react in a positive or negative way. This depends on how 
sensitive the individual is.  
 
7  Degree  of accessibility of adequate user information* 
presence and quality of the description flyer/misleading information/ appearance of the product 
 
Mushroom (and herbal products) contain a scale of different pharmacological and toxicological 
active substances. There is little pharmacological and toxicological literature about the known active 
substances. Moreover this literature varies in content, quality and accessibility.  
Because of this it is often difficult give a clear judgement about the harmfulness of these 
substances. Natural products are often mistakenly considered as beneficial and harmless. Moreover 
‘the harmlessness’ of it is praised by both users as retailers.  
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The sales in smart-shops can be an advantage, when this decreases the risk of misidentification / to 
switching with poisonous species (especially the switching of Psilocybe with the strong nefrotoxic 
Cortinarius is notorious). 
 
The impression exists that mushrooms are by far the most sold products of smart shops. Research 
clearly shows however that the information for users is not given properly by all Smartshops. Also 
the knowledge of the salesman in Smartshops turns out to be very varying. The information given in 
grow shops and head shops is very poor. 
 
The information flyers usually do not contain the expiry date. The nature of the possible unwanted 
effects (side effects) is not described; thus leaving the inexperienced user in uncertainty. The 
amount of active substances (psilocybin /psilocin) present in the mushrooms is not mentioned. 
Because of the variety of active substances, the user cannot determine which dosage of active 
substances he takes when he consumes a certain amount of magic mushrooms.  
 
8  Level of availability of the product 
 
In Smartshops the species Psilocybe, Panaeolus, Conocybe spp., Psilocybe semilanceata and the 
Psilocybe cubensis are often sold. Next to dried and fresh mushrooms, small grow kits are for sale. 
 
Magic Mushrooms is a widely sold in smart shops as an very effective product between a wide 
assortment of expensive, mainly new age placebo/”fake” products. Also they are offered in tourist 
shops where attributes as cannabis/coke pipes, T-shirts, badges etc. are sold. Magic Mushrooms 
are wide spread, because of the way they are sold. Mainly young foreigners are confronted with 
them. In Amsterdam there is a commercial trade-boom going on. 
 
Most of the Amsterdam people have used mushrooms more often. Mushroom consumption 
amongst Amsterdam users seems to be over it’s top and is, according to some decreasing again. 
Young foreign tourists, who flood the Amsterdam red-light district during the summertime and move 
from coffeeshop to coffeeshop, have also discovered the Smartshops. They form a group of new 
consumers, which have given the smart branch in the inner city a new impulse.  
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Mainly in the Amsterdam red-light district the number of smart shops has been largely increasing 
and the branch has been focussing increasingly on tourists. 
 
9.  Reliability of the quality of the product *  
production method/purity/toxicity by-products/location of production 
 
There are no product inspections. Of not one magic mushroom (and plant product) we know all the 
substances contained. Harmful components, added or not, can occur and affect the organs. The 
rising of more and more mixed and processed herbal products is contributing to the obscurity. 
The biotransformation method has yet been found on the Internet. When tryptamin is added to the 
substrate the amount of psilocybin increases while that of psilocin decreases. Biotransformation is 
the only way to increase the level of alkaloids.  
 
In the present situation a system of integral quality control, control and supervising in the chain from 
production to the supply to the consumer is lacking. Moreover it is not clear weather the user 
information, if available, is sufficiently based on facts. Because of the variety in contents of active 
substances, the user cannot determine which dose of active substances he takes when he 
consumes a certain amount of mushrooms.  
 
The variety in active substance is smaller in cultivated mushrooms then in wild grown mushrooms. 
Psilocybin is stable at room temperature. It stays conserved in dried mushrooms. When it is dried in 
temperatures above the 50 degrees Celsius it falls apart in non-active substances. 
 
    10.  Reliability of distribution and sale points, traders 
 
There is no product inspection. These products are mainly sold in Smartshops. A few of the owners 
of smart shops have a “criminal” past.  
The impression exists that there are relations on a small scale between sale points, trade, and 
producers on one hand and key figures in the organised (synthetic drugs) crime on the other hand.  
It pleas for the phenomenon ‘smart shops’, that this branch is nationally organized and is imposing 
itself ‘ethical’ and product-quality values, which is shown from the fact they asked champignon 
growers to grow these mushrooms for them. 
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11.  Nature and number of reports of incidents  
first aid hospitals/FAWE/NVIC 
 
The number of described cases concerning intoxications by mushrooms is relatively small (table 4.4 
of this report). There are only two fatal intoxications with Psilocybe spp. described. These 
intoxications are according to the author both not caused by intoxication by psilocybin. In 1982 there 
are in total 31 reports of clinic interventions because of intoxication with psilocin registered, 
throughout the whole United States of America. 
Until now there are no reports in the Netherlands, about serious incidents after using mushrooms. 
According the National Poison Information Centre (NVIC) informative questions were asked 
occasionally about intoxication with mushrooms until a while ago (about 2 to 3 times a month). 
Recently the number of information requests is increasing. During the period of time from the 9th of 
June 1997 till the 13th of August the NVIC has given information 17 times. The information served 
users of psychedelic mushrooms; varying in age between 15 and 39 (average age 20), for whom 
medical attention was needed because of intense acute health effects.  
The effects were mainly anxiety attacks, strong agitation and motorical restlessness, fear, 
hallucinations, confusion and visus impairment.  
The number of alarm reports is increasing since a couple of years. It is remarkable that the use of 
mushrooms can lead to intense panic or conditions of disintegration. With reports at the Central 
Post of Ambulance Transport concerning mushrooms,  it is usually necessary to transport the 
consumers to the First Aid of various city hospitals. This is a measurement for the seriousness of 
the panic. For as far as known this did not lead to deadly complications. 
It is remarkable that the alarm situations concerning mushrooms, often concern foreigners. The 
number of incidents is rather small compared to cannabis (dutch/etnic: 13, foreign: 24, of which 
transported to first aid/hospital: 23; in 1997). After transport 7 persons were taken in regarding 
XTC/mushrooms and were observed for 24 to 48 hours. All of them were discharged after recovery. 
No patient has died as a result of alarm situations after the consumption of these party drugs. 
 
Disturbance of peace and safety 
 
12.    Frequency and seriousness of nuisance for citizens around use and sales 
 
These products are mainly sold in Smartshops. Through the CRI(Dutch Central Police Intelligence 
Agency), with the help of available information from the police regions, a “quick scan" has been  
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done. The work group has send a list of questions about criminal activity and nuisance to those 
municipalities which are a member of the inner administrative Taskforce Safety and Addiction Care. 
Nuisance as a result of the sales or use of this product has not been reported. Magic mushrooms 
are still not seen as a party drug. Most of the users prefer a magic mushroom experience outside in 
nature or at home. Hallucinogens are considered not fit to be taken in discotheques by most of the 
'party people’. The dosage that is recommended by the smart shops is only used sporadic.  
 
13.    Does the substance lead to a decrease of violence inhibition in the user? 
 
A 'bad trip' can lead to feelings of anxiety and panic. 
 
14.    Does the substance influence the ability to react (ability to drive, operating equipment) 
 
The effects start after about 30 minutes and continue for usually less than 3 to 4 hours (6-12 mg). 
Sometimes the effects can last longer (up to 12 hours), depending on the dose.  
Different behaviour patterns usually occur under influence of hallucinogens. This can lead to 
dangerous situations, for example during driving and operating equipment. 
Psilocybin and psilocin affect the neurotransmitter serotonin. The effect is comparable to LSD. 
Especially the hallucinations of space- and time- travel are very vivid. The duration of the effects is 
shorter than that of LSD; between 2 and 4 hours. Because of the effects on perception it is obvious 
that doing psycho-motoric tasks in general and especially taking part in traffic is very risky. 
Someone who sees a crash barrier as a crawling snake cannot be marked as safe person in traffic. 
Psychologically, (strong) changes in perception of space and time can occur, and also mood 
swings. Higher dosages cause sense impairments and generally visual hallucinations. 
Acoustic hallucinations occur far less frequent. 
Euphoric feeling and sleepiness can occur. 
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Criminal involvement 
 
15.    Is there involvement of (organized) crime with production and trade 
 
Criminal involvement in production of and trade in eco-drugs and smart products is noticed to 
limited degree, but there is no impression, that this is at present(1997) has reached a worrisome 
scope. 
In the case of the "Kerkdrielse" mushroom growers there was nothing that gave or gives reason to 
assume that there are criminal groups which want to (let others) grow mushrooms(commercially) on 
a large scale. These growers were 'amateurs' which on their own turned a bad running champignon 
mushroom farm, with stakes and risks for themselves, into a lucrative company. 
At the Parquet-General there is not much known about criminal aspects of the use and trade of 
mushrooms. 
Two district parquets (Amsterdam and Den Bosch) have been questioned about the criminal 
aspects of magic mushrooms. Both parquets give the same message: There is no hard evidence of 
criminal involvement. There is however no reason to believe that this is not the case. In the district 
Den Bosch has the 'gap' created by the absence of the growers from Kerkdriel has quickly been 
filled by others. There is a lot of money to be made with the growing  and trade. 
The parquet in Amsterdam reports that there are no concrete indications for criminal involvement. 
However there are so many questions concerning the supply of magic mushrooms that it has been 
decided to do an investigation about criminal involvement under supervision of the Wallen manager. 
 
16.    Is there involvement of (organised) crime with production and trade in raw materials 
 
No information has been found. See 14 as well. 
 
 
 
Discussion points: consequences of measures 
 
Proportion of the risk of international-political problems concerning im- or export 
 
In the Netherlands (1998) hallucinogenic mushrooms were cultivated on a large scale, which were 
dried and crushed. The crushed magic mushrooms were then packed in small bags and sewed for 
closure. Afterwards transport to Germany (Keulen) followed, where it was sold under the excuse of 
"Duftkissen" by means of a distribution chain. 
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legislation applicable on comparable products 
 
Every product that is available in smart shops is brought under the general determinations of the 
Law of Goods(Note translator: law on food & supplements). 
Psilocybin and psilocin are the active substances in magic mushrooms and are named on List 1 of 
the Opium Law(Law on controlled substances). 
The Supreme Court has ruled that fresh Psilocybe mushrooms do not, but mushrooms treated in 
any way, do fall under the Opium Law. Growing mushrooms can according to the Supreme Court be 
a punishable act in preparation of an illegal act (11/18/1997, NJ 1998, 213). The court of law Den 
Bosch has judged in the basic procedure of this case, that growing mushrooms under certain 
circumstances are an act in preparation of an illegal act, according article 10a of the Opium Law. 
The circumstances where in this case that the grower was actively treating the mushrooms (active 
drying process). The courts opinion is that the mushrooms became an illegal preparation as meant 
in the opium law. 
This court of law has also judged that psilocin and psilocybin are no danger for the public health, but 
that a judge is not free to rule that psilocin and psilocybin are wrongly on list 1 of the Opium Law. 
This is up to the legislator. 
The provisional result of the ruling of the Supreme Court and the judgement of the court of law is 
that Psilocybe mushrooms "treated in any way” are under the control of List 1 of the Opium Law. 
The definitive status of magic mushrooms is still to be decided by the courts. 
 
Negative consequences for legal economic and industrial sectors in case of prohibition 
 
The sales of magic mushrooms is a large part of the Smartshops turnover.. 
There are some champignon mushroom growers who switched to growing Psilocybe mushrooms. 
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                                                                                                                                        Appendix 2 
 
 
1.     Composition risk assessment commission 
 
Min. Health VWS: direction GVM: plv chairman.                                     Sr. Drs. A. Cramer 
Min. Health VWS: direction of medicine provision (GMV)                           Sr. Drs. W.K. Scholten 
Inspection on health Care (IGZ)                                                          Sr. Dr. R.J.J.Hc. Lousberg 
Inspections for Goods and Veterinary cases (IW&V)                          Sr. Drs. B Kunstner* 
Trimbos research institute /Focal point                                                        Ms. Drs. M. van Laar 
Trimbos research institute /DIMS                                                                Ms. Dr I.P. Spruit 
Ministry of Justice                                                                               Ms. Mr. N. van der Arend 
Ministry of Justice/WODC                                                                   not present 
Ministry of Defence (OM/USD)                                                    Sr. Mr. J.J.T.M. Pieters 
CRI/Unit Synthetic Drugs (USD)                                                         Sr. A. Elissen 
Economic Control Service                                                                   not present 
Judicial Laboratory (GL)                                                                        Sr. Dr. H. Huizer 
National Intoxication Information Centre (NVIC)                                Ms. drs. I. de Vries 
Leids Universityl Medical Centre: Lab. for Toxicology                       Sr. Prof. Dr. F.A. de Wolff 
GG&GD Amsterdam                                                                           Sr . Dr. R. ter Haar 
University of Amsterdam: fac. Study of Law and Criminology          Sr. Drs. T. Nabben 
CAM coordinator/secretary                                                                 Ms. Dr. C.A. Rurgers 
 
 
2    Procedures for risk assessment 
 
There are three procedures, which vary only in speed: 
A. A very fast procedure, (fast assessment) for situations, which are an acute public health risk ( 
e.g. atropine). This procedure has to be finished within 24 hours. 
B. A reasonable fast procedure, (moderate assessment) for situations of which the public health risk 
is not acute, but is present within a short period of time. 12 days seems to be a reasonable period of 
time. 
C. A procedure upon request, where there is no strict limitation in time (preventive assessment). 
This procedure can take a couple of months. 
 
 
*represented by Ms. W. Kleinjan   27
The steps are the same in the three procedures: 
1. The report of a (suspected) new drug or the request for a risk assessment comes in at the 
coordination point through the network. Through Europol or the Focal Point (Trimbos) reports from 
other Member States of the European Union can come in. 
2. The coordination point to present asks the daily management to decide if a procedure is to be 
started. If so, then the coordination point will collect information about the new drug through it’s 
network. The information rapport will be made based upon the collected information. The 
information rapport will be send to all the members of the commission or to a selection of them. (4 
days) 
3. Based upon this information the members will individually to make an risk assessment through 
the score form, with the established criteria. If the procedure allows it, the outcome is discussed 
together. (2 days) 
4. The risk assessment forms will be collected and it’s contents evaluated by the coordination point. 
Based upon this the coordination point will make a risk assessment-rapport with conclusions and 
recommendations. (4 days) 
5. If possible the rapport will be presented to the members for commentary and to the daily 
management for approval (2 days). 
6. The risk assessment rapport will be presented to the minister of Public Health by the Head 
inspector FMT of the Inspection on health care. 
7. The procedure will be evaluated (facultative). 
 
 
3    Risk assessment criteria 
 
I. Individual health 
1. Level of risk concerning physical dependence 
2. Level of risk concerning mental dependence 
3. Level of risk concerning acute toxicity (besides the effect intended by the user) 
frequency and seriousness of complaints/ use of other substances/ dosages and variations of those/ 
common way of intake/ frequency of use/effects which the user cannot perceive, do but influence 
behaviour. 
4. Level of risk concerning chronic toxicity (see 3) 
 
II. Public Health 
5. Level of risk concerning the proportion and frequency of (the increase of) the use (inter) 
nationally. 
6. Level of risk concerning the vulnerability of the user   28
age/experience/knowledge/circumstances 
7. Level of risk caused by the absence of adequate usage information 
presence and quality of flyer/deceiving information/appearance of the product 
8. Level of risk concerning the availability of the product 
9. Level of risk caused by unreliable quality of the product 
production method/ purity/ toxic by-products/ location of production 
10. Level of risk caused by the unreliability of the way of distribution, sales points and traders 
11. Level of risk measured by the nature and proportion of reports of incidents 
first aid hospitals/EHBO/ National Intoxication Information Centre 
 
III. Disturbance of peace and safety 
12. Level of risk concerning nuisance (frequency and seriousness) for citizens around sale and use 
13. Level of risk in relation to the decrease of violence inhibition in the user 
14. Level of risk caused by the influence on the ability to react (driving, operating equipment) of the 
user 
 
IV. Criminal involvement 
15. Level of risk concerning possible involvement of (organised) crime in the production and trade 
16. Level of risk concerning possible involvement of (organised) crime in the production and trade in 
raw materials 
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4.  Risk assessment table (Level of risk concerning...) 
 
Name of person:                                            Name substance: 
 
I. INDIDVIDUAL HEALTH  1 2 3 4  5  Score
(1) Physical dependence  no Very low possible high  very high
(2) Mental dependence  no Very low possible high  very high
(3) Acute intoxication  no  Very low possible high  very high
   
            
(4) Chronic intoxication  no Very low possible high  very high
   
            
II. PUBLIC HEALTH   
(5) Proportion & frequency of use  no Very low possible high  very high
   
            
            
(6) Vulnerability of user  no Very low possible high  very high
   
            
            
(7) Unavailable user information  no Very low possible high  very high
   
(8) Availability of product  no Very low possible high  very high
   
(9) Unreliable quality product  no Very low possible high  very high
   
            
(10) Unreliable way of distribution  no Very low possible high  very high
   
(11) Nature and number incidents  no Very low possible high  very high
   
III. DISTURBANCE OF PEACE   
(12) Frequency and seriousness  no Very low possible high  very high
   
            
(13) Act of violence by user no Very low possible high  very high
   
            
(14) Influence ability to react  no Very low possible high  very high
   
            
IV. CRIMINAL INVOLVEMENT   
(15)Criminal involvement final product  no Very low possible high  very high
   
(16) Criminal involvement raw materials no Very low possible high  very high
 
   30
                                                                                                                           
   Appendix 3 
 
Possible measures for risk-control 
 
There are roughly five possible categories: 
1. no action 
2. monitoring, 
3. prevention, 
4. targeted measures directed at production and trade 
5. prohibition (nationally/ internationally) 
 
In the area of monitoring and prevention there are various existing instruments, which can be used 
(e.g. DIMS, information programs). 
Measures and prohibitions are required to be based upon the law. There are four laws suited: the 
Opium Law, the Law for Medicine Provision, the Law of Goods and the Code of Penal. 
 
Law of Goods 
 
The Law of Goods decides that trade of goods with a medical orientated advertisement is prohibited 
(art. 19). There is also decided that action may be taken when the public health is in danger by a 
disputable product (art. 18). At last there is the possibility to make standardization through a 
Common Measure of Management to decide what amount of an active substance is allowed in a 
product (art. 4). 
 
Law of Medicine Provision 
 
According to the European Court of Justice the LMP is applicable to all the active pharmaceutical 
substances (see arrest of the 16th of April concerning the term medicine). However, the final 
judgement about every specific substance is always up to the national judge. The remaining criteria 
of the LMP, pharmaceutical form, and advertisement as a medicine, making medical claims play a 
part in this. What can also play a part is weather the substance is (has been) on the market as a 
registered medicine in the Netherlands. Most of the party drugs are used to influence the processes 
of the brain but are sold in pharmaceutical shape (tablets, powder, capsules) but are not sold with a 
medical claim. 
The LMP decides that for preparing and trading  of medicines a permit is needed and that a 
medicine can only be traded if a registration has been required from the College for Judgement of   31
Medicine. The LMP is mainly focussed on the legal production and trade and on registration of 
medicines. 'Legal' registration of the LMP for party drugs is impossible, because of the absence of a 
no medical indication. 
In May 1999 a special work group (IGZ/OM, researching offences LMP' 19th of May 1999) has 
concluded that the LMP in its present form is not really suitable to deal with the abuse of medicine 
(as party drugs or doping) adequately because of the low penalization. A proposition has been done 
to solve this problem (making the penalization higher in case of offence of some articles of law by 
bringing them under the Law of Economic Offences). The Counsel of Ministers will discuss the bill of 
law in spring of the year 2000.  
 
Opium Law   
 
The classification under the Opium Law means a total prohibition on import/export, production, trade 
and possession. In the Opium Law a difference has been made between list 1 substances 
(unacceptable risk for public health) and list 2 substances (acceptable risk) concerning penalization. 
No difference has been made between the different substances (in risk level) on list 1. 
A limitation is that list 1 can only be rearranged nationally (list 2 can only be rearranged if the 
Psychotropic Substances Pact in UN-relation is rearranged). So new substances can only be put on 
list 1 (with the highest penalization). 
With the Opium Law (adequate) action can be taken against all operations with party drugs. There 
is a possibility for persons or institutions to apply for leave of the Opium Law at the Minister of 
Public Health. However these permissions are only given to certain ends (production & trade of 
medicine, research and instructive ends).  
 
Code of Penal 
 
With the Code of Penal art. 174 actions can be taken against deliberate selling (the dealer probably 
knows it is harmful) etc. of harmful goods where the harmful character is deliberately concealed. 
However the provability forms a remaining problem here. 
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                                                                                                                               Appendix 4 
 
 
Chronological description risk assessment procedure magic mushrooms 
 
On September the 27th 1999 the policy Executive Board of the Ministry of Public Health submitted 
a request to start a risk assessment procedure concerning magic mushrooms. 
 
On October the 1st 1999 the daily management of the Coordination point Assessment and 
Monitoring new drugs (CAM) decided a risk assessment procedure for magic mushrooms would be 
started. 
 
On October the 1st 1999 the CAM asked for information from the soundboard group members and 
on November the 24th 1999 the information rapport (the collected, analysed and summarized 
information) has been send to all the members of the risk assessment commission with the request 
to make an individual risk assessment. 
 
On December the 9th 1999 the risk assessment commission gathered to make a joint risk 
assessment. 
 
On January the 10th 2000 a concept of the rapport has been send to the risk assessment 
commission for commentary. 
 
On the 8th of February the CAM has presented the final rapport to the daily management for 
approval and on the 23rd of February it is approved. 
 
In total the procedure has taken 5 months. 
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1 Terminology 
 
Crime: when the law is broken with full awareness and this is the usual manner of making an 
earning. 
 
Euphoria: heightened feeling of well-being and unfounded optimism 
 
Empathic: the ability to imagine the feelings of others 
 
Habituation: obtained tolerance 
 
Organized crime: in groups, in networks or other connections. There has to be a matter of the use of 
violence to defend positions etc. 
 
Risk assessment: A (scientific) evaluation of probability of occurrence of known or potential negative 
effects (as well quantitative as qualitative) for (public) health, public order and society. 
 
Risk: An estimation of the probability with which and the level with which a negative result for the 
(public) health, public order and society can occur. 
 
Hallucination: sense perception without the sense input causing it 
 
Illusion: Incorrect interpretation of sense input 
 
Mutagenic:  Mutations (in DNA) beneficial or bringing about  
 
Nuisance: An unwanted social situation, caused by a.o. theft, aggression and (street) violence, 
derogatory behaviour and disturbance of public order 
 
Teratogenetic: promoting or bringing about deformities (in the unborn fruit)  
 
Tolerance: Low sensitivity for the pharmaceutical action of a substance 
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Addiction: Dependence, which manifests by signs of withdrawal. Physical: for example shaking, 
shivering, redness of face and neck, impairments of sense capacity. Mentally: restlessness, 
agitation, anxiety, depression, and hallucinations. 
 
2 Abbreviations 
 
CAM    Coordination point and Monitoring new drugs 
2-CB   4-broom-2,5  dimethoxyphenethylamin 
CNS    Central Nerve System     
DIMS   Drugs Information and Monitoring System 
EMCDDA European  Monitoring  Center for Drugs and Addiction 
GABA   Gamma Amino Butric Acid (neurotransmitter) 
GBL   Gamma-butyrolacton 
GHB   Gamma-Hydroxy-Butyrate 
LSD    Lysergic Acid Diethyl-amide 
MBDB   1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane 
MDMA 3,4-methylenedioxy-N-methylamphetamine ( = XTC) 
MTA   4-methylthioamphetamine 
VLOS   Branch organisation of Smartshops 
UN   United  Nations 
LMP    Law on Medicine Provision 
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On the legal status of Psilocybe mushrooms – By Ananda Schouten 
 
UN & National laws. 
The mandate of the INCB is described on their website as follows: ‘It is the boards responsibility to promote 
government compliance with the provisions of the drug control treaties and to assist them in this effort.” 
This implies that when there is doubt about how a law, which has come to existence trough the UN drug 
treaties, should be to interpreted, a country should seek advise at the INCB. 
 
The INCB of the UN is very clear in their statement that Psilocybe mushrooms are not controlled by the UN  
convention on psychotropic substances. If Psilocybe mushrooms are not controlled by this convention, then 
may a Nation apply the laws flowing from this convention, more strict than the convention provides? 
  
Article 23 of the UN states that “A party may adopt more strict or severe measures or control than those 
provided by this Convention if, in its opinion, such measures are desirable or necessary for the protection or 
the public health and welfare.” 
The CAM rapport and the study on psilocybin clearly show that such measures are not desirable nor 
necessary for the protection of the public health and welfare. 
 
Several nations which wanted to ban magic mushrooms, like Germany and Swiss needed to create new 
laws, because they concluded that the existing laws, that came to be as a result of the UN convention on 
psychotropic substances of 1971, do not apply to Psilocybe mushrooms.  
Since the UK has signed the UN convention, it’s citizens including those charged for possession of 
mushrooms, may expect that if the UN states Psilocybe mushrooms are not controlled by the convention, the 
crown will respect this treaty. 
 
Why plants, containing illegal substances are not controlled. 
In the process of formulating the UN convention of 1971 this topic was well discussed. Controlling such 
plants (or mushrooms in this case) would bring about a lot of problems. Wild organic material, which contains 
controlled substances can be found anywhere. Magic mushrooms or some out of thousands of such plants 
may grow and sundry in your lawn.  
Many other substances that are freely available everywhere are listed as controlled in this convention: 
For instance: MMDA, the active ingredient or nutmeg. Red poppy somniverum contains morphine, opium 
&heroin. Phalaris contains DMT. Potato’s contain Diazepam and lormetazepam. 
These substances are prepared in ways that makes them preparations under the UN convention if dried 
Psilocybe mushrooms are considered preparations. Nutmeg are even powdered. If magic mushrooms are 
controlled, then these products are controlled as well. 
 
Intolerability and unrealizability of a magic mushroom ban on basis of the existing laws. 
The Netherlands is an excellent example of the problems that arise from a ban on treated magic mushrooms. 
Treated or prepared mushrooms are illegal in the Netherlands. Passively dried mushrooms are legal, 
because they have not undergone any preparation. There is no way to see how a mushroom became dry. 
Then how dry is dry? What percentage of water needs to be evaporated, before a mushroom ceases to be a 
mushroom and begins to become a preparation? If a mushroom is packaged, does it then cease to be a 
mushroom? Is it allowed to put mushrooms on a plate? What about the fact that magic mushrooms are 
cooled and packed with the intent to keep them fresh and thus legal? for The vagueness goes beyond 
comprehension and beyond extent. It is to big to describe here.  
The police force, which is already overloaded with work (which does prevent citizens from getting hurt) is 
confronted with all this vagueness. The Police finds this vagueness impossible enforce. Should the police 
inspect if there is enough water in magic mushrooms or how they are packed? This seems absurd, but is the 
direct result of a ban trough existing laws. It would leave a greater quantity of loophole than law. The police in   36
the Netherlands finds itself unable to enforce these laws. It would also result in a great consumption of time 
of the courts, as vague laws, result in many unnecessary cases. If banning is something a nation wants to 
do, then the lawmakers should do so by making a law, which is fit to the task. 
 
About prohibition of Psilocybe Mushrooms 
When magic mushrooms are sold trough legally operating, tax paying retailers, they sell them in a clearly 
recognisable form. This means that this leaves no room for cleverly disguised ‘magic’ chocolate bars, ‘magic 
tea’ and many other unrecognisable forms. Products like that are easily mistaken for candy by children. 
Retailers that sell magic mushrooms want to prevent such events and provide regulation by not selling to 
minors and provide information for safe use. 
 
Poisonous mushrooms of the Amanita  species are often confused by media and authorities with  Psilocybe 
mushrooms. This confusion should not be underestimated. Amanita’s are also referred to as Magic 
mushrooms by the general public. In contrary to Psilocybe, Amanita’s can be deadly and contain a whole 
different type of active substances.  
 
Both the CAM risk assessment and the study on psilocybin clearly show that there is no need to protect 
public health with a ban on magic mushrooms.  Psychopharmacology (2004) 172:145–156
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Abstract Rationale: Serotonin (5-Hydroxytryptamine, 5-
HT) receptors play an important role in perception, affect
regulation and attention. Pharmacological challenge with
the 5-HT2A agonist psilocybin (PY) is useful in studying
the neurobiological basis of cognition and consciousness.
Objective: Investigation of dose-dependent effects of PY
on psycho(patho)logical and physiological parameters.
Methods: Eight subjects received placebo (PL), and 45
(“very low dose, VLD”), 115 (“low dose, LD”), 215
(“medium dose, MD”), and 315 (“high dose, HD”) mg/kg
body weight PY. The “Altered States of Consciousness
Rating Scale” (5D-ASC), the “Frankfurt Attention Inven-
tory” (FAIR), and the “Adjective Mood Rating Scale”
(AMRS) were used to assess the effects of PY on psy-
cho(patho)logical core dimensions, attention, and mood. A
24-h electrocardiogram (EKG) was recorded and blood
pressure was measured. Plasma concentrations of thyroid-
stimulating hormone (TSH), prolactin (PRL), cortisol
(CORT), adrenocorticotropic hormone (ACTH), and stan-
dard clinical chemical parameters were determined. Re-
sults: PY dose dependently increased scores of all 5D-ASC
core dimensions. Only one subject reacted with transient
anxiety to HD PY. Compared with PL, MD and HD PY led
to a 50% reduction of performance in the FAIR test.
“General inactivation”, “emotional excitability”, and
“dreaminess” were the only domains of the AMRS
showing increased scores following MD and HD PY.
The mean arterial blood pressure (MAP) was moderately
elevated only 60 min following administration of HD PY.
Neither EKG nor body temperature was affected by any
dose of PY. TSH, ACTH, and CORT plasma levels were
elevated during peak effects of HD PY, whereas PRL
plasma levels were increased following MD and HD PY.
Conclusion: PY affects core dimensions of altered states of
consciousness and physiological parameters in a dose-de-
pendent manner. Our study provided no cause for concern
that PY is hazardous with respect to somatic health.
Keywords Psilocybin · Dose–effect study ·
Psycho(patho)logy · Neuroendocrinology ·
Cardiovascular effects · Altered states of consciousness
Introduction
The indolealkylamine psilocybin (PY, 4-phosphoryloxy-
N,N-dimethyltryptamine) is the main psychoactive prin-
ciple of hallucinogenic mushrooms such as Psilocybe
cubensis and Psilocybe semilanceata. PY interacts mainly
with serotonergic neurotransmission (5-HT1A, 5-HT2A,
and 5-HT2C receptor subtypes). Equilibrium dissociation
constants (Ki) are 6 nM for the 5-HT2A receptor subtype
and 190 nM for the 5-HT1A subpopulation (McKenna et
al. 1990). PY and its active metabolite psilocin (PI)
have—in contrast to lysergic acid diethylamide (LSD)—
no affinity for dopamine D2 receptors (Creese 1975). In a
receptor-blocking study, we showed that the psychotropic
effects of PY could be blocked completely by pre-
treatment with the 5-HT2A preferential antagonist ke-
tanserin (Vollenweider et al. 1998) suggesting that PY-
induced effects are mediated primarily via activation of 5-
HT2A receptor subtypes. However, some of the psycho-
tropic effects of PY might be due to downstream effects
on other neurotransmitter systems. For example, we
recently demonstrated in a PET study using the D2-
receptor ligand [11C] raclopride that PY increases striatal
dopamine (Vollenweider et al. 1999). The enhanced
dopaminergic activity correlated with derealization/de-
personalisation phenomena and euphoria. Corresponding
functional interactions of central dopaminergic and sero-
tonergic systems have been demonstrated (Kapur and
Remington 1996). The pharmacology of PY is reviewed
in a paper by Passie et al. (2002). Aside from the popular
(illicit) use as a recreational drug (Cuomo et al. 1994;
Lohrer and Albers 1999; Supprian et al. 2001), PY can
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the neurobiological basis of altered states of conscious-
ness (ASC) (Vollenweider et al. 1997; Gouzoulis-
Mayfrank et al. 1998; Vollenweider et al. 1999; Vollen-
weider and Geyer 2001). Recent investigations revealed
that the serotonin (5-HT) receptor system is of basic
importance also in the modulation of cognitive functions
such as memory and attention (Meneses 1998; Buhot et
al. 2000; Ellis and Nathan 2001). Depending on the
context, activation or inhibition of 5-HT2A receptors leads
to an improvement or an impairment of working memory
function (Williams et al. 2002). Hence, the 5-HT2
receptor agonistic mode of action of psilocin (PI, 4-
hydroxy-N,N,-dimethyltryptamine), the first and pharma-
cologically active metabolite of PY (Hasler 1997;
Lindenblatt et al. 1998) makes this “classic” hallucinogen
also an interesting compound to investigate brain mech-
anisms underlying attention. In view of the diverse and
widespread use of PY, its pharmacological and toxico-
logical properties in humans must be closely investigated
in order to estimate the safety of PY.
Our literature review revealed two human studies on
the acute somatic effects of PY from 1959 and 1961
(Isbell 1959; Hollister 1961) and one study published in
1999 by Gouzoulis-Mayfrank et al. (Gouzoulis-Mayfrank
et al. 1999) using a single dose of PY in eight subjects.
Isbell found a clinically irrelevant, although statistically
significant, elevation of systolic blood pressure after
administration of 86  g/kg body weight PY, but not after
114  g/kg. Hollister’s clinical-chemical measures of
serum cholesterol, alkaline phosphatase, cholinesterase,
and aspartatamino-transferase revealed no differences
between baseline blood samples and samples taken 2 h
post-dose. Gouzoulis et al. (Gouzoulis-Mayfrank et al.
1999) found no significant response of cortisol, prolactin,
or growth hormone on administration of a single moderate
dose of PY (200  g/kg). In the same trial, weak elevations
of systolic blood pressure and body temperature were
noted. In a human study by Strassman and Qualls (1994),
intravenous N,N- dimethyltryptamine (DMT), a halluci-
nogenic compound chemically related to PI, dose depen-
dently raised prolactin and cortisol plasma levels.
The primary aim of this study was to explore the
potential dose–response relationship of PY on multiple
levels, encompassing various (neuro-)psychological and
physiological parameters. The second aim was to estimate
the drug safety of PY for further use in human challenge
studies and to appraise possible associated risks.
Materials and methods
Subjects
Eight volunteers (four male and four female; mean age 29.5 years,
range 22–44 years) were recruited from university and hospital staff
by word of mouth and agreed to participate in the study with
written informed consent. Subjects were healthy according to
physical examination, detailed clinical-chemical blood analysis,
and electrocardiogram. All subjects were screened by structured
psychiatric interview based on the DIA-X computerized diagnostic
expert system (Wittchen and Pfister 1997). Personal and family
histories of major psychiatric diseases as well as personal histories
of illicit drug use were employed as exclusion criteria. The
screening procedure was supplemented by standard psychometric
instruments (Freiburg Personality Inventory FPI, Fahrenberg et al.
1984; State Trait Anxiety Inventory, Trait form STAI-X2; Laux et
al. 1981; and Hopkins Symptom Checklist SCL-90, Derogatis et al.
1973). Since the personality trait factors “rigidity” and “emotional
lability” were identified to be predictors of negative experiences
during ASC (Dittrich 1993), scores exceeding two SD from the
mean value of normative data in the respective subscales of the FPI
(i.e., “openness” and “neuroticism”) were used as exclusion
criteria. Apart from sporadic use of cannabis, our subjects had no
or very limited experience with psychoactive drugs. All subjects
were of normal weight (mean body mass index 21.4, range 18.5–
23.5) and all female volunteers had a regular menstrual cycle and
did not receive oral contraceptives.
Substances
PY for neurochemical stimulation was obtained through the Swiss
Federal Office for Public Health, Department of Pharmaceutics and
Narcotics, Bern. PY capsules (1 mg and 5 mg) were prepared at the
Pharmacy of the Cantonal Hospital of Aarau, Switzerland. Quality
control comprised tests for identity, purity and uniformity of
content. PY and lactose placebo were administered in gelatin
capsules of identical appearance.
Study design
The study protocol was approved by the ethics committee of the
University Hospital of Z rich. Administration of PY to healthy
subjects was authorized by the Swiss Federal Office for Public
Health, Department of Pharmaceutics and Narcotics, Bern. Ac-
cording to our within-subject study design, each volunteer received
placebo (PL) and four different doses of PY in random order on five
experimental days at least 2 weeks apart. PY dosages were as
follows: very low dose (VLD) = 45  g/kg body weight; low dose
(LD) = 115  g/kg; medium dose (MD) = 215  g/kg; and high dose
(HD) = 315  g/kg. Our own investigations (Hasler 1997; Hasler et
al. 1997) revealed that identical doses of PY relative to body weight
cause comparable plasma concentration–time profiles of PI. We
therefore preferred to administer doses relative to body weight
rather than absolute amounts of PY. Both volunteers and investi-
gators were blind with respect to the experimental condition. To
minimize confounding effects of circadian rhythms on hormone
levels, drug dosing took place at approximately the same time. In
all female volunteers, the experiments were performed during the
early follicular phase of their menstrual cycles. Experienced
psychiatrists supervised all experiments.
Psychometric scales
Dimensions of ASC
The rating scale 5D-ASC (Dittrich 1998; Dittrich et al. 1999) is a
visual-analogue scale suited to depict alterations in waking con-
sciousness—including changes in mood, perception, experience of
self and environment, and thought disorders—regardless of the
inducing factor(s) (Dittrich 1996, 1998). Score-sums of the respec-
tive items make up the following five dimensions of the 5D-ASC:
“oceanic boundlessness” (OB) measures derealization and deper-
sonalization phenomena associated with positive emotional states
ranging from heightened mood to euphoria. “Anxious ego dissolu-
tion” (AED) subsumes dysphoric mood states such as anxiety and
fearful delusions, arising mainly from ego-disintegration and loss of
self-control phenomena. The 5D-ASC main scale “visionary
restructuralization” (VR) is constructed of items circumscribing
146“elementary hallucinations,” “synesthesia,” “changed meaning of
percept,” “facilitated recollection,” and “facilitated imagination.”
The “auditory alterations” (AA) scale summarizes acoustic phe-
nomena empirically found during ASC, and the dimension “reduc-
tion of vigilance” (RV) depicts states of drowsiness and impairment
of alertness and cognitive performance. The scale “global ASC
score” (G-ASC) is constructed by addition of the scores from the
OB, AED and VR subscales. Our subjects were asked to complete
5D-ASC rating scales 150 min and 300 min after drug administration
and instructed to thereby rate their experience from the intervals 0–
150 min and 150–300 min, respectively. To facilitate comparison of
scales among each other, 5D-ASC data are presented as percentage
values indicating percentage of maximum absolute scores.
Affective states
The adjective mood rating scale (AMRS) (Janke and Debus 1978)
represents a multidimensional psychometric test developed for
repeated measures of mood states. In practice, a list of 60 adjectives
depicting mood states (e.g. “active,” “lost in thought,” “sociable”)
were presented to the subjects 10, 95 and 275 min and 24 h after
drug intake. The volunteers were instructed to choose from four
possible answers (“not at all,” “somewhat,” “quite,” or “strongly”
appropriate) to rate gradually to what extent each adjective
characterizes their actual mood state. The AMRS consists of 15
subscales that can be subsumed interpretatively to seven domains of
affective states: performance-related activity (efficiency-activation
and concentration), general inactivation (inactivation, tiredness and
drowsiness), extroversion-introversion (extroversion plus inverted
scores from the introversion scale), general well being (self-
confidence and heightened mood), emotional excitability (excit-
ability, sensitivity and aggressiveness), anxiety-depressiveness
(anxiety and depressed mood), and dreaminess.
Frankfurt attention inventory
Dose-dependent effects of PY on sustained attention were assessed
140 min after drug administration using the Frankfurt Attention
Inventory (FAIR; Moosbrugger and Oehlschl gel 1996). This paper
and pencil test measuring concentration behavior consists of 640
stimuli with high similarity that have to be discriminated against
each other within 6 min. The FAIR test quantifies aspects of
concentration behavior displayed in four test scores: “marker
value” (MV) expresses comprehension of test instructions, “per-
formance value” (PV) informs on the amount of attentively
processed test items during a defined test period, “quality value”
(QV) depicts the amount of attentively made decisions respective to
the total amount of decisions, and the “continuity value” (CV)
reflects the extent of continuously upheld concentration over the
entire test duration. The FAIR task provides good test–retest
reliability expressed as a Crohnbachs alpha between 0.85 and 0.91.
Physiological measures
Electrocardiogram
Electrocardiograms (EKG) were continuously registered for 24 h
by use of a portable two-channel Holter recorder, model 90205,
supplied by Spacelabs, Burdick. EKG monitoring was started 1 h
before drug application, and the subjects were instructed to stop the
recorder and remove the electrodes the following day. Signal
quality was monitored with a Cardysuny 501X multichannel
electrocardiograph (Fukuda ME, Kogyo, Japan), and data analysis
was performed using a medical computer Model 90104A from
Spacelabs, Burdick. The following EKG standard parameters were
examined: mean, minimum and maximum heart rates (min 1),
number of supraventricular and ventricular extrasystoles (n),
maximum S-T elevation (mm and  ), maximum S-T depression
(mm and  ), and number of pauses (asystoles; n).
Blood pressure and body temperature
Blood pressure was measured using a Riva-Rocci sphygmanometer
(Erka, Switzerland) 30 min before drug intake and at 5, 30, 60, 90,
120, 165 and 210 min. The axillary body temperature was recorded
at the same time points using a Terumo digital clinical thermometer
C2O2.
Blood pressure data expressed as mean arterial pressure (MAP)
values were calculated as follows: MAP (mm Hg) = diastolic blood
pressure + 1/3 (systolic blood pressure   diastolic blood pressure).
Maximum rise of MAP above PL (PL values averaged from 0–
210 min post-drug administration) is indicated as D MAX MAP.
Blood sampling, blood chemistry, and analysis of hormones
Blood samples for quantification of hormones and clinical-chem-
ical parameters were drawn from an indwelling intravenous
catheter into vacutainer tubes 20 min before drug administration
and at 105 min and 300 min. Plasma was separated by centrifu-
gation (15 min at 3000 rpm) immediately after sampling and stored
at  27 C until analysis. The following blood parameters were later
determined at the Institute of Clinical Chemistry of the University
Hospital of Z rich: sodium (Na+), potassium (K+), chloride (Cl ),
urea (UR), creatinine (CR), lactate dehydrogenase (LDH), gamma
glutamyltransferase (GGT), alkaline phosphatase (AP), aspartate
aminotransferase (ASAT), alanine aminotransferase (ALAT), thy-
roid-stimulating hormone (TSH), prolactin (PRL), cortisol (CORT),
and adrenocorticotropic hormone (ACTH). Besides sampling into
EDTA-containing vacutainer tubes, blood samples for quantifica-
tion of ACTH were additionally stabilized by adding 2000 KIU of
aprotinin (Trasylol). Analytical methods used for quantification of
clinical-chemical parameters and accuracies for the respective
assays were as follows: Kinetic Jaff -reaction (CR; accuracy 1.7%
CV) (Bonini et al. 1992), enzyme-kinetic assays (LDH; CV 2.9%)
(Knedel et al. 1986), GGT (CV 0.4%) (Bonini et al. 1992), ASAT
(CV 3.1%) (Bonini et al. 1992), ALAT (CV 2.4%) (Bonini et al.
1992), and AP (CV 2.5%) (Knedel et al. 1986), ion-selective
potentiometric assays (Na+; CV 0.5%), K+ (CV 1.0%) and Cl  (CV
0.8%) (Bonini et al. 1992), electro-chemiluminescence technology
(TSH; CV 3.9%) and CORT (CV 2.8%), chemiluminescence
immunometric methods (ACTH; CV 8.8%) and PRL (CV 9.6%)
(Robinson and Nelson 1983), and urease-GLDH assay (UR; CV
2.6%) (Bonini et al. 1992). Additional standard hematology
analysis, including automated complete blood counts, was per-
formed prior to the first and at the end of the last experimental day.
Statistical analysis
All statistical calculations were performed using the STATISTICA
for windows software, version 6.0. According to the within-subject
design of the study, every subject served as her/his own control in
order to minimize effects of intraindividual variation in physiolog-
ical and psychological test scores. Univariate two-way ANOVAs
with treatment (PL and four doses of PY) and observation time as
repeated measures were used to reveal differences between PL and
drug conditions for all parameters. When significant main effects or
interactions were detected with the ANOVA procedure, post-hoc
pair-wise comparisons were performed using the Tukey HSD tests.
Significance levels of main effects are cited in the text. Probability
values of P<0.05 were considered statistically significant.
Trapezoid calculation of AUC values (“Area under the data–
time curve”) for analysis of blood pressure and body temperature
data was performed in Microsoft Excel 2000, using the equation
AUC 0 t ðÞ ¼
X n 1
i¼0
tiþ1   ti
2
MAPi þ MAPiþ1 ðÞ :
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Acute psychological effects of psilocybin
First subjective changes were perceived by the volunteers
usually 20–40 min following administration of PY. Peak
effects were reported after 60–90 min, lasting for another
60–120 min. PY effects then gradually subsided and were
completely worn off at the 6-h point. Already, the
threshold dose of 45  g/kg PY (VLD) was rated clearly
psychoactive by most of our volunteers. Slight drowsiness
and increased sensitivity and intensification of pre-
existing mood states were most prominent effects at this
dosage level. LD, MD and HD PY (115, 215 and 315  g/
kg) dose dependently induced changes in mood states,
sensory perception (including colorful visual illusions,
complex scenic hallucinations and synesthesias), as well
as alterations in perception of time, space, and self.
Typically, the experiences after MD and HD PY were
rated positive, with retrospective statements ranging from
“pleasurable” to “ineffably beautiful.” “Magic” or “phan-
tasmagoric” were terms often used to circumscribe a PY
experience. However, one volunteer (male, 23 years)
reacted with pronounced anxiety to HD PY. He reported a
fearful experience marked by depressed mood and fear of
losing control. Without pharmacological intervention, his
anxiety during the plateau phase of PY action gradually
subsided and the dysphoric reaction was completely
resolved six hours post-drug ingestion.
Dimensions of ASC
Figure 1 shows detailed psychometric data from the 5D-
ASC rating scale regarding four doses of PY compared
with PL condition. As assessed by both rating intervals
(0–150 min and 150–300 min after drug administration),
PY dose dependently increased scores of all 5D-ASC
scales [main effect of drug: OB (F4,28=8.58, P<0.001),
VR (F4,28=7.26, P<0.001), AA (F4,28=2.72, P<0.05), RV
(F4,28=3.07, P<0.05), G-ASC (F4,28=8.85, P<0.001)],
whereas for the dimension “anxious ego dissolution” a
significance level of P<0.05 was just missed [AED
(F4,28=2.39, P<0.07)]. When calculated with mean scores
from our eight subjects, least-squares linear regressions
show excellent linearity between PY dose and scores of
the three core 5D-ASC dimensions (OB, AED, VR) as
well as the Global ASC score G-ABZ. Correlation
coefficients (r) of the linear regression models of the
examined rating interval 0–150 min were 0.98 for OB
(P<0.003), 0.97 for AED (P<0.005), 0.98 for VR
(P<0.004), and 0.99 for G-ABZ (P<0.002), respectively.
Affective states
Table 1 summarizes time- and dose-dependent effects of
PY on affective states, as assessed with the AMRS. A
three-way ANOVA revealed significant AMRS scale  
treatment   time interaction (F72,504=1.68, P<0.001).
Subsequent post-hoc analysis showed significant increas-
Fig. 1 Subjective effects of psilocybin. Percentage scores from the altered states of consciousness rating scale 5D-ASC (mean€SEM,
n=8). Scores indicate percentage of theoretical scale maxima
148es in the AMRS dimensions “general inactivation” (PY
215  g/kg, t0+95 min: P<0.001; PY 315  g/kg, t0+95 min:
P<0.001 and PY 315  g/kg, t0+275 min: P<0.01),
“emotional excitability” (PY 315  g/kg, t0+95 min:
P<0.001) and “dreaminess” (PY 215  g/kg, t0+95 min:
P<0.001; PY 315  g/kg, t0+95 min: P<0.001; PY 315  g/
kg, t0+275 min: P<0.001 and PY 315  g/kg, t0+24 h:
P<0.01), relative to PL. Increased introversion at the peak
of the drug effect (t0+95 min) is reflected by significantly
decreased scores on the AMRS scale “extroversion-
introversion” (PY 215  g/kg: P<0.01 and PY 315  g/
kg: P<0.001).
Frankfurt attention inventory
PY exerted no significant influence on the FAIR scores
MV (F4,28=0.58, P=0.687) and QV (F4,28=1.39, P=0.261).
In contrast, administration of PY led to a significant
decrease in the FAIR scores PV (F4,28=12.28, P<0.00001)
and CV (F4,28=11.23, P<0.00001) as shown in Table 2.
Thereby PV and CV were not significantly influenced by
VLD and LD PY, whereas MD and HD PY decreased the
respective scores to approximately 50% of values ob-
tained under PL condition.
Acute physiological effects of psilocybin
Electrocardiogram
ANOVA calculations revealed no differences in any of
the examined parameters of the Holter-24 h EKG. No
evidence for a PY-induced change of cardiac electro-
physiology was found. In Table 3, all EKG results and F
and P values from the respective statistical calculations
are resumed. In order to compactly display the EKG
results, all data were classed in three intervals: the
baseline interval (“interval 1”; t0 1 h–t0), the interval of
acute effects of PY (“interval 2”; t0–t0+6 h), and the
interval covering the time from the end of subjective drug
action up to 24 h (“interval 3”; t0+6 h–t0+24 h).
Table 1 Subjective effects of psilocybin. Dose-dependent scores in the seven domains of affective states from the adjective mood rating
scale (AMRS) (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45  g/kg) LD (115  g/kg) MD (215  g/kg) HD (315  g/kg)
Rating 1 (baseline)
Performance-related activity 19.1€1.4 19.3€1.0 18.9€1.7 17.4€0.7 16.6€1.4
General inactivation 16.5€1.6 15.0€2.2 16.3€2.3 13.9€1.0 17.6€2.6
Extroversion-introversion 4.4€1.1 4.6€0.9 5.1€1.1 3.5€0.6 3.0€0.9
General well being 20.0€1.7 20.3€1.2 22.6€1.4 19.5€1.9 18.6€2.2
Emotional excitability 15.4€0.7 15.3€0.7 15.6€1.1 16.5€1.0 16.7€1.7
Anxiety-depressiveness 8.3€0.2 9.0€0.8 8.0€0.0 9.0€0.6 9.9€1.1
Dreaminess 6.3€0.8 6.4€0.7 5.9€0.6 6.0€0.5 5.9€0.7
Rating 2 (t0+95 min)
Performance-related activity 17.8€1.2 16.4€0.9 15.1€1.4 14.9€1.2 14.9€1.7
General inactivation 14.6€1.8 18.0€2.5 21.0€2.2 23.5€1.9*** 24.9€2.0***
Extroversion-introversion 5.3€0.7 2.8€1.4 1.9€1.2 0.3€1.7**  1.9€1.4***
General well being 18.6€1.9 20.4€1.5 20.9€1.8 22.4€2.0 22.0€2.5
Emotional excitability 14.9€1.3 15.0€0.9 15.0€0.9 17.8€1.7 20.6€2.2***
Anxiety-depressiveness 9.0€0.7 8.6€0.5 8.7€0.4 8.9€0.4 11.6€2.6
Dreaminess 6.4€0.7 7.3€0.9 7.6€0.7 11.6€1.0*** 10.6€0.8***
Rating 3 (t0+275 min)
Performance-related activity 18.3€1.3 17.8€1.2 16.3€1.0 16.6€0.8 16.0€0.9
General inactivation 13.6€0.7 16.0€2.1 17.0€1.5 17.0€1.7 21.6€2.3**
Extroversion-introversion 4.8€1.0 4.6€0.9 2.7€1.1 2.0€1.4 1.6€1.6
General well being 19.6€1.9 20.1€1.5 21.1€1.6 21.1€1.3 22.6€1.3
Emotional excitability 14.6€0.9 14.9€1.6 15.1€1.1 15.5€1.2 15.7€1.2
Anxiety-depressiveness 8.3€0.3 8.5€0.5 8.6€0.4 8.4€0.4 8.7€0.5
Dreaminess 6.0€0.7 6.4€0.9 6.7€0.8 7.3€0.9 10.6€0.5***
Rating 4 (t0+24 h)
Performance-related activity 19.7€1.1 20.0€1.3 20.6€1.2 18.7€1.1 16.3€1.3
General inactivation 14.0€0.7 14.3€0.9 14.7€0.9 18.4€2.0 18.7€1.4
Extroversion-introversion 5.4€1.0 5.3€0.6 5.3€0.3 3.0€1.1 1.4€1.8
General well being 19.7€1.7 19.8€1.3 21.0€0.9 18.7€1.0 17.9€1.3
Emotional excitability 15.9€1.1 14.8€1.3 15.4€0.9 15.3€1.5 16.4€0.9
Anxiety-depressiveness 9.4€0.7 8.4€0.4 8.9€0.5 9.3€0.7 10.6€1.1
Dreaminess 5.1€0.5 5.1€0.5 5.6€0.7 7.3€1.0 8.4€0.8**
* P<0.05
** P<0.01
*** P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
149Blood pressure and body temperature
No statistically significant main effect of PY on MAP
(F4,28=1.81, P=0.155), maximum rise of MAP above
averaged PL values (D MAX MAP; F3,21=1.04, P=0.396),
and area under the MAP–time curve (AUC(0–t) MAP;
F4,28=2.43, P=0.071) was found. ANOVA analysis,
however, detected a significant dose   time interaction
(F28,196=2.34, P=0.0004). As depicted in Fig. 2a, b, a
trend of PY to increase blood pressure is apparent.
Subsequent post-hoc tests revealed that blood pressure
(systolic blood pressure and MAP) was significantly
increased only 60 min following administration of HD
PY, relative to PL (P<0.001). Diastolic blood pressure
was significantly elevated (P<0.05) only 90 min follow-
ing intake of HD PY. Time courses of averaged MAP
values following four doses of PY and PL are shown in
Table 2 Effects of psilocybin on sustained attention. Scores from the Frankfurt attention inventory (FAIR; mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45  g/kg) LD (115  g/kg) MD (215  g/kg) HD (315  g/kg)
Rating at 140 min post-drug ingestion
Marker value (MV) 0.991€0.003 0.991€0.003 0.993€0.003 0.984€0.009 0.987€0.002
Performance value (PV) 480.6€33.4 456.5€25.8 455.8€31.9 260.7€25.0 *** 258.0€42.0 ***
Quality value (QV) 0.943€0.014 0.959€0.014 0.961€0.004 0.927€0.029 0.910€0.025
Continuity value (CV) 455.9€34.4 438.9€28.0 439.4€32.3 242.6€27.0 *** 243.6€43.3 ***
*P<0.05
**P<0.01
***P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
Table 3 Electrocardiographic data following placebo and four doses of psilocybin (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin Main effect
of drug
Main effect
of drug
VLD
(45  g/kg)
LD
(115  g/kg)
MD
(215  g/kg)
HD
(315  g/kg)
F (4, 28)
values
P values
Interval 1 (baseline; t0 1 h–t0)
Mean heart rate (min 1) 78€5 79€5 75€3 85€6 82€6 0.601 0.665
Minimum heart rate (min 1) 57€4 62€3 58€3 60€4 65€4 0.589 0.673
Maximum heart rate (min 1) 126€6 120€6 130€5 130€7 112€7 2.280 0.086
Supraventricular extrasystoles (n) 1€1 1€1 1€1 1€1 1€1 2.058 0.114
Ventricular extrasystoles (n) 2€1 1€1 2€2 1€1 1€1 2.492 0.067
Maximum S-T elevation (mm) 1.3€0.4 2.0€0.4 2.5€0.5 1.6€0.3 1.6€0.2 1.570 0.210
Maximum S-T elevation (slope,  ) 27€7 45€8 46€5 46€4 37€6 1.230 0.321
Maximum S-T depression (mm) 0.3€0.2  0.1€0.2  0.3€0.3  0.2€0.5 0.0€0.2 0.918 0.467
Maximum S-T depression (slope,  ) 10€4 17€6 18€6 18€5 14€4 1.178 0.341
Pauses (n) 0€0 0€0 0€0 0€0 0€0 0.148 0.963
Interval 2 (t0 –t0+6 h)
Mean heart rate (min 1) 85€5 82€5 82€5 87€6 84€4
Minimum heart rate (min 1) 60€4 62€4 61€2 60€3 63€2
Maximum heart rate (min 1) 141€5 128€6 137€8 140€8 131€6
Supraventricular extrasystoles (n) 21€6 7€3 19€9 5€2 4€3
Ventricular extrasystoles (n) 16€7 2€2 5€4 5€3 3€2
Maximum S-T elevation (mm) 1.5€0.4 2.2€0.6 2.6€0.5 1.9€0.3 1.6€0.3
Maximum S-T elevation (slope,  ) 35€8 46€8 49€5 50€4 43€7
Maximum S-T depression (mm) 0.0€0.2  0.4€0.3  0.4€0.3  0.4€0.3  0.2€0.1
Maximum S-T depression (slope,  ) 8€4 16€6 14€8 20€6 13€4
Pauses (n) 0€0 0€0 0€0 0€0 0€0
Interval 3 (t0+6 h –t0+24 h)
Mean heart rate (min 1) 73€3 74€5 70€4 77€5 72€2
Minimum heart rate (min 1) 55€3 60€4 53€3 55€2 55€1
Maximum heart rate (min-1) 121€2 115€6 118€2 116€6 111€2
Supraventricular extrasystoles (n) 9€3 11€5 10€3 4€1 8€4
Ventricular extrasystoles (n) 8€3 6€3 6€2 4€2 7€3
Maximum S-T elevation (mm) 1.1€0.3 2.1€0.6 2.0€0.4 1.8€0.3 1.6€0.3
Maximum S-T elevation (slope,  ) 25€6 38€7 40€5 40€4 34€5
Maximum S-T depression (mm) 0.2€0.2 0.0€0.2 -0.5€0.5 -0.3€0.5 0.3€0.2
Maximum S-T depression (slope,  ) 10€4 16€6 14€6 18€5 14€4
Pauses (n) 1€1 1€1 1€1 1€1 1€1
150Fig. 2a, and systolic and diastolic blood pressure follow-
ing HD PY and PL are depicted in Fig. 2b.
Axillary body temperature was not significantly influ-
enced by any of the applied doses of PY (F4,28=0.94,
P=0.452). ANOVA of the corresponding area under the
data–time curves also did not reveal statistical differences
between the groups. Effects of PY on blood pressure and
body temperature are summarized in Table 4.
Neuroendocrine data
ANOVA of the hormone plasma concentrations revealed
a statistically significant main effect of drug only for PRL
(F4,28=6.41, P=0.0009), whereas significant dose   time
interactions were found for all monitored hormones
(TSH: F8,56=3.95, P=0.0009; PRL: F8,56=4.68, P=
0.0002; ACTH: F8,56=4.23, P=0.0005; and CORT:
F8,56=2.43, P=0.025). Tukey HSD post-hoc pairwise
comparison with corresponding values after PL treatment
revealed significantly elevated plasma levels for all
measured parameters in blood samples collected
105 min following HD PY (TSH following PY 315  g/
kg, P<0.01; PRL following PY 315  g/kg, P<0.001;
ACTH following PY 315  g/kg, P<0.01; and CORT
following PY 315  g/kg, P<0.05). PRL plasma concen-
trations were already increased following MD PY (PRL
following PY 215  g/kg, P<0.01). In the plasma samples
collected 300 min post-drug administration, all hormone
concentrations were back to pre-dose levels. Detailed data
for time- and dose-dependent effects of PY on plasma
levels of hormones are given in Table 5.
Blood chemistry and hemogram
With the exception of two liver enzymes determined in
plasma samples taken 105 min following administration
of HD PY (ASAT and GGT; see beneath), PY did not
elicit statistically significant responses from any of the
analyzed clinical-chemical blood parameters. Mean plas-
ma concentrations of all monitored compounds as well as
F and P values deriving from ANOVA calculations of
main effects of drug are summarized in Table 6. Statis-
tically significant drug   time interactions were found
Fig. 2 a Average mean arterial blood pressure (MAP) following
four doses of psilocybin and placebo, respectively (n=8). b Systolic
and diastolic blood pressures following administration of placebo
and HD psilocybin (mean€SEM, n=8)
Table 4 Effects of psilocybin on blood pressure and body temperature (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45  g/kg) LD (115  g/kg) MD (215  g/kg) HD (315  g/kg)
MAP1 93€3.9 97€3.9 101€3.6 100€4.2 101€3.9
D MAX MAP2 – 14€4.4 16€4.7 15€3.9 21€5.3
AUC (0–t) MAP3 21447€883 22199€853 23069€926 22935€983 23158€981
Body temp ( C) 36.5€0.1 36.6€0.1 36.4€0.2 36.5€0.1 36.6€0.1
AUC (0–t) temp4 8394€31 8428€16 8370€36 8408€21 8418€28
1 Averaged mean arterial pressure (mmHg; 5–210 min post-drug administration)
2 Maximum rise of MAP above averaged placebo values (mmHg)
3 Area under the MAP–time curve (mmHg   min)
4 Area under the body temperature–time curve ( C   min)
151only for the liver enzymes ASAT (F8,56=2.26, P=0.036)
and GGT (F8,56=2.15, P=0.046). Consecutive post-hoc
pairwise comparison revealed significantly elevated con-
centrations of these two parameters in the plasma samples
collected 105 min following administration of HD PY
(ASAT P<0.001; GGT P<0.002), relative to PL.
Comparison of hemograms from blood samples pre-
ceding the first and following the last experimental day
revealed no differences whatsoever in any parameter.
None of the hematological parameters of any subject was
out of normal range.
Discussion
Acute psychological effects of psilocybin
Psilocybin (PY) dose dependently induced important
alterations of perception, affect, ego-functions, and
attention in all subjects. The phenomenological concept
of ego-functions (e.g., ego-identity, ego-vitality, ego-
demarcation, etc.) and their perturbations in the course of
ASC or psychopathology is explained by Scharfetter
(1981). Analysis of the 5D-ASC scores revealed that only
MD and HD PY led to a relevant loosening of ego-
boundaries (OB/AED) and to pronounced changes of
perception (VR). The loosening of the demarcation
between self and environment was generally accompanied
by insight and experienced as “touching” or “unifying
with a higher reality” (OB). In one subject, however, HD
PY transiently led to a disturbance of ego functions that
was experienced with pronounced anxiety (AED). Also,
only MD and HD PY induced intermittent geometric and
complex visual hallucinations, whereas VLD and LD PY
led to illusions in terms of intensification or distortion of
visual perception (VR). PY also amplified or altered
acoustic perception (AA), but no auditory hallucinations
occurred during any of the experiments. All PY-induced
symptoms were worn off completely 6–8 h after drug
administration.
As expressed in scores from the AMRS mood rating
scale, increased general inactivation, introversion, and
dreaminess were seen robustly in all subjects. A statis-
tically significant increase in the AMRS subscale
“dreaminess” was still present in the rating 24 h following
administration of HD PY, presumably representing the
need to reflect and integrate the content of a profound
hallucinogen experience well into the next day. Admin-
istration of both VLD and LD PY induced a mental
condition described by one volunteer as “switching
between the worlds”. In this state, normal waking
consciousness is intermittently pervaded with transient
and unstable drug states in a wavelike pattern, but the
“insightfulness” typically experienced after higher doses
of PY is absent. When distinct hallucinogenic effects
were perceived following the two lower doses, they were
short lasting and only present for about 1–2 h. The effect–
time course following VLD PY supports our previous
findings (Hasler 1997; Hasler et al. 1997), that PY effects
arise and wear off with a certain blood level of PI
(approximately 4–6 ng PI/ ml plasma). This opposes the
alternative hypothesis that PY might initiate secondary
downstream brain mechanisms whose subjective effects
could well outlast the presence of pharmacologically
relevant amounts of the active compound in the blood-
stream. We abstained from monitoring plasma concen-
tration–time profiles of PI, since reliable determination of
this highly unstable phenolic compound requires a
sophisticated and costly analysis technique (Hasler et al.
1997; Lindenblatt et al. 1998).
Interestingly, several subjects could not clearly state in
retrospect on which experimental day they had received
Table 5 Neuroendocrine effects of psilocybin. Dose-dependent plasma concentrations of hormones (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin
VLD (45  g/kg) LD (115  g/kg) MD (215  g/kg) HD (315  g/kg)
Sampling 1 (baseline, t0 20 min)
Thyroid-stimulating hormone (TSH [mU/l]) 1.30€0.15 1.62€0.13 1.54€0.13 1.40€0.16 1.27€0.14
Prolactin (PRL [ g/l]) 16.7€5.5 16.0€5.4 14.6€4.3 15.5€5.7 14.8€2.8
Adrenocorticotropic hormone (ACTH [ng/l]) 21€6 17€5 17€4 18€6 12€2
Cortisol (CORT [nmol/l]) 432€59 336€54 378€77 382€50 385€71
Sampling 2 (t0+105 min)
Thyroid-stimulating hormone (TSH [mU/l]) 1.24€0.16 1.41€0.09 1.50€0.13 1.54€0.16 1.66€0.22**
Prolactin (PRL [ g/l]) 9.5€2.0 12.8€4.6 14.5€5.3 22.4€7.7** 28.0€7.5***
Adrenocorticotropic hormone (ACTH [ng/l]) 20€5 19€4 25€5 42€14 50€12**
Cortisol (CORT [nmol/l]) 348€50 353€85 443€47 522€82 567€74*
Sampling 3 (t0+300 min)
Thyroid-stimulating hormone (TSH [mU/l]) 1.16€0.15 1.38€0.19 1.15€0.09 1.20€0.13 1.18€0.18
Prolactin (PRL [ g/l]) 12.4€2.7 9.0€1.6 9.1€1.7 9.7€2.0 12.9€2.9
Adrenocorticotropic hormone (ACTH [ng/l]) 18€4 15€3 15€2 14€2 15€2
Cortisol (CORT [nmol/l]) 353€54 306€64 289€60 294€57 344€61
* P<0.05
** P<0.01
*** P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
152VLD and LD PY, or MD and HD PY, respectively. The
fact that VLD and LD PY as well as MD and HD PY have
common “qualities” in respect of subjective effects is also
mirrored in the results from the FAIR attention test.
Individual scores for the “performance value” and
“continuity value” were almost identical following VLD
and LD PY, and MD and HD PY, respectively. Following
MD and HD PY, both FAIR scores were reduced to
roughly 50% of the scores reached after PL, VLD, or LD
PY. The strongly impaired performance in the FAIR test
under MD and HD PY is difficult to appraise, since the
obvious reduction of attentional abilities due to 5-HT2A
receptor overstimulation may well be confounded by the
(also drug-induced) lack of motivation to perform well in
this task, as stated by several subjects.
Scores from the 5D-ASC dimension RV indicate that
vigilance is reduced less following HD PY than after MD
PY. We propose that following PY in a dosage of 315  g/
kg body weight, noradrenergic neurotransmission is
significantly stimulated as well, leading to an overcom-
pensation of the more inactivating effects of predomi-
nantly 5-HT stimulation induced by lower PY doses. This
reasoning is in line with the hypothesis that hallucinogen-
induced inhibition of Raphe neurons leads to an increased
activity of adjacent noradrenergic neurons of the locus
coeruleus (Marek and Aghajanian 1998; Aghajanian and
Marek 1999).
Table 6 Plasma concentrations of clinical chemical parameters following administration of four doses of psilocybin (mean€SEM, n=8)
Placebo Psilocybin Psilocybin Psilocybin Psilocybin Main effect
of drug
Main effect
of drug
VLD
(45  g/kg)
LD
(115  g/kg)
MD
(215  g/kg)
HD
(315  g/kg)
F (4, 28)
values
P values
Sampling 1 (baseline, t0 20 min)
Natrium (Na+ [mmol/l]) 139€2 140€1 141€1 139€2 140€1 0.764 0.558
Potassium (K+ [mmol/l]) 4.0€0.1 3.9€0.1 4.0€0.1 4.0€0.1 4.0€0.1 0.891 0.482
Chloride (Cl  [mmol/l]) 109€3 104€3 100€3 102€5 108€3 2.053 0.114
Urea (UR [mmol/l]) 4.2€0.4 5.1€0.6 4.6€0.4 4.6€0.6 4.3€0.3 2.220 0.093
Creatinine (CR [ mol/l]) 83€6 87€6 82€4 82€4 83€4 0.732 0.578
Lactate dehydrogenase (LDH [U/l]) 272€13 308€18 295€20 295€21 285€13 2.028 0.118
g-Glutamyltransferase (GGT [U/l]) 13€1 13€1 13€1 13€1 13€2 1.380 0.266
Aspartate aminotransferase
(ASAT [U/l])
16€2 18€1 17€2 18€2 16€1 1.548 0.206
Alanine aminotransferase
(ALAT [U/l])
13€1 14€2 15€2 16€3 13€1 1.490 0.232
Alkaline phosphatase (AP [U/l]) 74€9 75€11 78€11 76€11 71€10 0.347 0.844
Sampling 2 (t0+105 min)
Natrium (Na+ [mmol/l]) 138€3 139€1 140€1 138€3 140€1
Potassium (K+ [mmol/l]) 3.8€0.1 3.8€0.1 4.0€0.1 4.0€0.1 4.0€0.1
Chloride (Cl  [mmol/l]) 108€2 103€2 100€1 104€3 107€2
Urea (UR [mmol/l]) 4.0€0.4 4.9€0.6 4.4€0.3 4.2€0.5 4.0€0.3
Creatinine (CR [ mol/l]) 79€6 82€4 84€5 78€5 72€3
Lactate dehydrogenase (LDH [U/l]) 265€18 306€17 318€29 329€30 331€20
g-Glutamyltransferase (GGT [U/l]) 13€2 13€1 13€2 14€1 16€3**
Aspartate aminotransferase
(ASAT [U/l])
16€2 18€2 19€2 19€2 24€3***
Alanine aminotransferase
(ALAT [U/l])
13€2 15€1 16€2 16€2 18€3
Alkaline phosphatase (AP [U/l]) 74€9 76€10 78€11 83€12 80€12
Sampling 3 (t0+300 min)
Natrium (Na+ [mmol/l]) 137€3 140€1 140€1 138€3 141€1
Potassium (K+ [mmol/l]) 3.8€0.1 3.8€0.1 3.9€0.1 3.9€0.1 3.8€0.1
Chloride (Cl  [mmol/l]) 104€3 104€2 101€2 103€3 109€2
Urea (UR [mmol/l]) 3.7€0.3 4.6€0.6 4.0€0.3 3.9€0.4 3.7€0.3
Creatinine (CR [ mol/l]) 76€6 80€4 82€4 78€4 78€3
Lactate dehydrogenase (LDH [U/l]) 271€13 315€11 309€16 317€21 302€13
g-Glutamyltransferase (GGT [U/l]) 12€1 13€1 13€1 14€1 15€2
Aspartate aminotransferase (ASAT
[U/l])
16€2 19€3 19€3 18€2 20€2
Alanine aminotransferase
(ALAT [U/l])
13€2 15€2 16€2 14€2 17€2
Alkaline phosphatase (AP [U/l]) 76€10 79€10 81€12 78€11 77€10
* P<0.05
** P<0.01
*** P<0.001 compared with placebo condition (Tukey HSD post-hoc test)
153Acute physiological effects of psilocybin
Due to its general use for clinical purposes, effects of PY
on blood pressure are mainly presented as MAP values
(Table 4), representing the average blood pressure during
a cardiac cycle. Maximum rises of MAP above averaged
PL MAP values within 210 min following drug admin-
istration were calculated for every dosage level of PY and
labeled D MAX MAP. Corresponding absolute peak MAP
values for every PY dosage level can be calculated by
simple addition of the averaged MAP value following PL
(93 mmHg; Table 4) and the D MAX MAP value of the
respective PY dose. For example, the averaged absolute
peak MAP value after administration of HD PY was
114 mmHg (93 mm MAP for PL plus 21 mm D MAX
MAP for HD). As shown in Fig. 2a, compared with PL,
the MAP is significantly elevated only 60 min following
ingestion of HD PY. Looking only at averaged values, the
short-lasting elevation of blood pressure following HD
PY is no cause for concern, but individual values can be
considered critical. Maximum individual values for
systolic and diastolic blood pressure registered 60 min
following application of HD PY were 180/110 mmHg
(female, 29 years) and 170/120 mmHg (male, 24 years),
respectively. Detailed inspection of the psychometric
scales 5D-ASC and AMRS as well as personal reports
gave no evidence for excessive stress or anxiety at this
time point. By contrast, subject 4 (male, 23 years), who
reported great anxiety, did not have significantly elevated
blood pressure. The increase of MAP during peak effects
of HD PY is not surprising because cardiovascular
regulation is partially mediated by central 5-HT2 and 5-
HT1A receptor activation (Ramage 2001). As a comple-
tion to the “D MAX MAP” parameter describing
momentary and short-lasting blood pressure peaks, com-
parison of “Areas under the MAP–time curve” (AUC(0 t)
MAP) allows a quantitative assessment of changes in
blood pressure over the entire duration of PY action.
None of the applied doses of PY led to AUC(0–t) MAP
values different from the AUC(0–t) MAP value calculated
from PL data. Despite the possibility of a short-lasting
moderate elevation of blood pressure, in healthy humans
without pre-existing medical conditions, no cardiovascu-
lar complications must be expected from administration
of PY.
As shown in Table 5, administration of PY led to an
increase of plasma concentrations of all analyzed hor-
mones (TSH, PRL, ACTH, and CORT) in samples
collected 105 min following drug administration, i.e.,
during peak effects of PY. PY-induced changes in plasma
levels of TSH, PRL, ACTH and CORT have not been
previously reported. By the 300-min point, all endocrine
parameters were back to baseline values. Due to a
pronounced variability in plasma levels, statistically
significant differences in plasma concentrations relative
to the PL condition were reached for all hormones only
following HD PY, and for PRL also following MD PY. It
is noteworthy that only PRL levels in plasma samples
taken 105 min post-HD PY (28.0€7.5) were out of the
normal physiological range (3.4–24.1  g/l). Taking into
account that CORT plasma levels follow a circadian
rhythm, it is difficult to distinguish between drug effect
and physiological daily fluctuations. The effect of circa-
dian endocrine fluctuation was controlled to some degree
by starting the experiments at the same time each day. It
is unlikely that increased ACTH and CORT plasma
concentrations following HD PY are an expression of
stress, because no correlation between CORT levels and
scores of the anxiety depicting 5D-ASC subscale AED
(r=0.035) were found. An increase of ACTH and CORT
plasma concentrations as a direct result of 5-HT2 receptor
stimulation is not surprising, because both animal and
human studies suggest that pharmacological stimulation
of 5-HT mechanisms activates the hypothalamo-pituitary-
adrenal (HPA) axis, resulting in a release of ACTH and
corticosteroids into the blood stream (Fuller 1981;
Holmes et al. 1982; Van de Kar et al. 2001). Following
5-HT2 receptor stimulation, hypothalamic neurosecretory
transducer cells liberate corticotropin releasing hormone
(CRH), leading to an increase of ACTH and CORT
plasma concentrations. Our findings are in line with the
results of a study by Gouzoulis-Mayfrank et al. (1999)
comparing psychological and physiological effects of
single moderate doses of d-amphetamine, 3,4-methylene-
dioxyethylamphetamine (MDE) and PY. In their investi-
gation, administration of approximately 200  g/kg PY
also led to a statistically non-significant increase of
CORT plasma concentrations. In contrast, their adminis-
tration of MDE induced a robust increase of CORT
plasma concentrations in all volunteers. These findings
suggest that acute stimulation of 5-HT release (as it is
caused by MDE), is more important for activation of the
HPA-axis than direct agonistic action at the 5-HT2
receptor.
PY-induced increase in 5-HT activity is also reflected
by an elevation of PRL plasma levels following admin-
istration of MD and HD PY. This finding was not
unexpected, because release of PRL from the anterior
pituitary is controlled by inhibitory tuberoinfundibular
dopaminergic neurons and by stimulatory 5-HT mecha-
nisms (Prescott et al. 1984; Van de Kar et al. 1985). That
is, dorsal raphe nucleus 5-HT neurons that project to the
hypothalamus appear to be involved in the secretion of
PRL (Meltzer and Nash 1988).
The finding of a moderate, but statistically significant
increase of TSH plasma levels following administration
of HD PY is difficult to interpret, because functional
relationships between the hypothalamic-pituitary-thyroid
(HPT) axis and 5-HT mechanisms are not well understood
and still controversially discussed (Krulich 1982; Man-
nisto 1983; Duval et al. 1999). Some experimental
findings from animal studies indicate that the central 5-
HT system has an inhibitory influence on TSH secretion
(Mitsuma and Nogimori 1983), whereas others propose
the absence of a significant role for 5-HT in the
physiological release of TSH (O’Malley et al. 1984).
Yet other researchers suggest that 5-HT increases TSH
release into the bloodstream, probably by increasing TRH
154(thyroid-releasing hormone) production or by facilitating
the pituitary TSH response to TRH (Silva and Nunes
1996). Our finding of elevated TSH blood levels follow-
ing 5-HT2 receptor challenge is consistent with the
hypothesis of stimulation of the HPT axis by 5-HT
mechanisms. Neuroendocrinological research studies us-
ing pre-treatment with selective 5-HT receptor agonists
and antagonists might contribute to a better understanding
of this issue.
Statistical analysis of plasma concentrations of a
multitude of clinical chemical markers (Table 6) revealed
that PY has an effect solely on two liver enzymes: ASAT
and GGT. Thereby, only HD PY led to a statistically
significant, although clinically irrelevant, short-term
increase of these enzymes. It is noteworthy that also the
transiently increased ASAT and GGT plasma concentra-
tions were not out of normal physiological ranges [ASAT:
10–31 U/l (female) and 10–34 U/l (male); GGT: 7–32 U/l
(female) and 11–50 U/l (male)]. In blood samples taken
300 min following HD PY, ASAT and GGT values were
back to pre-dose levels and no longer significantly
different from respective concentrations determined under
the PL condition. We interpret the finding of a transient
elevation of ASAT and GGT following HD PY as a sign
of non-specific increase of liver enzyme activity as it is
often seen in “liver sensitive” subjects following admin-
istration of a multitude of drugs (Fried 2000).
We see two methodological limitations for the present
study. First, the moderate number of eight subjects may
lead to some distortion of the results, whereby a putative
bias is expected to be most pronounced for psychological
variables. Parameters with small effect sizes are unlikely
to reach the level of statistical significance and therefore
minor effects, e.g., following lower doses of PY, could
have been missed. Second, one might argue that the
highest dose of PY (315 mg/kg) used in this study is not a
“real” high dose, and some effects of PY would be clearly
apparent only following higher doses of PY. To the best
of our knowledge, no controlled clinical studies in
humans have been conducted using higher doses of PY.
For safety reasons, we decided to not use more PY
because we were not willing to expose our subjects to a
potentially more stressful drug effect at this early stage of
investigations.
Conclusions
Our investigations provided no cause for concern that
administration of PY to healthy subjects is hazardous with
respect to somatic health. However, as our data revealed
tendencies of PY to temporarily increase blood pressure,
we advise subjects suffering from cardiovascular condi-
tions, especially untreated hypertension, to abstain from
using PY or PY-containing mushrooms. Furthermore, our
results indicate that PY-induced ASC are generally well
tolerated and integrated by healthy subjects. However, a
controlled clinical setting is needful, since also mentally
stable personalities may, following ingestion of higher
doses of PY, transiently experience anxiety as a conse-
quence of loosening of ego-boundaries.
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